1
|
Alson S, Henic E, Hansson SR, Sladkevicius P. Correlation of adenomyosis features to live birth rates after the first IVF/ICSI treatment, when using the revised Morphological Uterus Sonographic Assessment group definitions. Acta Obstet Gynecol Scand 2024. [PMID: 39382305 DOI: 10.1111/aogs.14986] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2024] [Revised: 08/21/2024] [Accepted: 09/25/2024] [Indexed: 10/10/2024]
Abstract
INTRODUCTION Data regarding the impact of adenomyosis on the outcomes after in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment are conflicting. Standardized diagnostic criteria are prerequisites for studying a potential association between adenomyosis and IVF/ICSI treatment outcomes. This study aims to examine the cumulative live birth rate (CLBR) after the first IVF/ICSI treatment in women with or without direct or indirect features of adenomyosis, using the revised Morphological Uterus Sonographic Assessment (MUSA) group definitions. MATERIAL AND METHODS This was a prospective cohort study of 1037 women aged 25-≤39 years, undergoing their first IVF/ICSI treatment between January 2019 and October 2022. The presence of MUSA features of adenomyosis was assessed prior to treatment start. RESULTS The CLBR after the first IVF/ICSI treatment was 424/1037 (40.9%, 95% CI, 37.9-43.8) in the total cohort. Women with direct features of adenomyosis had lower CLBR, 25/102 (24.5%; 95% CI, 17.5-31.5) than women without, 399/935 (42.7%; 95% CI, 39.5-45.8), p < 0.001. The adjusted relative risk (aRR) for live birth for women with direct features of adenomyosis compared to women without was 0.62 (95% CI, 0.43-0.88), p = 0.007. Direct features were associated with a higher risk of miscarriage after frozen embryo transfer, aRR 2.88 (95% CI, 1.49-5.57), p = 0.002. Women with indirect features had a lower CLBR [50/188 (26.6%, 95% CI, 20.3-32.9)] than women without [399/935, (42.7%, 95% CI, 39.5-45.8)], aRR 0.58 (95% CI, 0.45-0.75), p < 0.001. For features located in the inner myometrium, the aRR for live birth was 0.29 (95% CI 0.11-0.74), p = 0.010 and for the outer myometrium 2.61 (95% CI 1.42-4.8), p = 0.002. An interrupted junctional zone was the single feature that impacted CLBR the most. CONCLUSIONS The presence of direct or indirect MUSA features of adenomyosis correlates to reduced live birth rates in women undergoing their first IVF/ICSI treatment. Features located in the inner myometrium, particularly an interrupted junctional zone, reduced the chance of live birth the most, whereas location in the outer myometrium was associated with higher chances of live birth. Systematic ultrasound examinations should be considered for women scheduled for IVF/ICSI treatment, for adequate counseling on the chances of successful treatment.
Collapse
Affiliation(s)
- Sara Alson
- Department of Clinical Sciences, Obstetric, Gynecological and Prenatal Ultrasound Research, Lund University, Malmö, Sweden
- Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden
- Reproductive Medicine Center, Skåne University Hospital, Malmö, Sweden
| | - Emir Henic
- Reproductive Medicine Center, Skåne University Hospital, Malmö, Sweden
- Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Stefan R Hansson
- Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden
- Department of Clinical Sciences, Unit for Translational Obstetric Research, Lund University, Sweden
| | - Povilas Sladkevicius
- Department of Clinical Sciences, Obstetric, Gynecological and Prenatal Ultrasound Research, Lund University, Malmö, Sweden
- Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
2
|
Orlov S, Sladkevicius P, Rivano Eckerdal I, Jokubkiene L. Morphological changes of endometriomas during pregnancy and after delivery detected using ultrasound. Fertil Steril 2024:S0015-0282(24)02219-2. [PMID: 39243849 DOI: 10.1016/j.fertnstert.2024.08.355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2024] [Revised: 08/26/2024] [Accepted: 08/30/2024] [Indexed: 09/09/2024]
Abstract
OBJECTIVE To assess changes in morphology and size of endometriomas during pregnancy and after delivery. DESIGN This was a prospective observational cohort study performed during 2013-2024 at a tertiary care center (Ultrasound Unit, Department of Obstetrics and Gynecology, Skane University Hospital, Malmo, Sweden). Women were offered repeated ultrasound examinations every month during pregnancy and thereafter at 3 and 12 months after delivery. Ultrasound examinations were performed either transvaginally or transabdominally depending on the gestational week and assessability of the ovaries. SETTING University hospital, tertiary care center. PATIENT(S) Pregnant women with an ovarian cyst suggestive of endometrioma based on subjective assessment were eligible and those with the pregnancy that continued beyond gestational age of 22 weeks were included. In total, 57 women were included. INTERVENTION(S) Pregnancy. MAIN OUTCOME MEASURE(S) Changes in morphology (cyst type, cyst content, and signs of decidualization) and size of the endometrioma and the largest solid component were assessed during follow-up ultrasound examinations. RESULT(S) During pregnancy, endometriomas changed in morphology in 42/57 women (74%; 95% confidence interval [CI], 60-84) and decreased in size in 42/57 women (74%; 95% CI, 60-84). Decidualization of endometrioma was observed in 33/57 women (58%; 95% CI, 44-71) and was detected first time at gestational age of 17 weeks (median, interquartile range, 15-22; range, 6-29). The size of endometriomas decreased although the size of solid components increased from gestational age of 22+0 weeks. Signs of decidualization disappeared after delivery. CONCLUSION(S) Three out of four endometriomas undergo morphological changes during pregnancy. Decidualized endometrioma may mimic borderline malignancy, however, changes regress after delivery. Knowing the natural behavior of endometriomas during pregnancy is crucial to reducing the risk of misclassification of endometriomas as malignant masses. Follow-up ultrasound examination after delivery helps to reassure the benign nature of the cyst.
Collapse
Affiliation(s)
- Sofie Orlov
- Obstetric, Gynaecological and Prenatal Ultrasound Research, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden; Department of Obstetrics and Gynaecology, Skane University Hospital, Malmo, Sweden; Department of Obstetrics and Gynaecology, Ystad Hospital, Ystad, Sweden.
| | - Povilas Sladkevicius
- Obstetric, Gynaecological and Prenatal Ultrasound Research, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden; Department of Obstetrics and Gynaecology, Skane University Hospital, Malmo, Sweden
| | - Isis Rivano Eckerdal
- Department of Obstetrics and Gynaecology, Skane University Hospital, Malmo, Sweden
| | - Ligita Jokubkiene
- Obstetric, Gynaecological and Prenatal Ultrasound Research, Department of Clinical Sciences Malmo, Lund University, Malmo, Sweden; Department of Obstetrics and Gynaecology, Skane University Hospital, Malmo, Sweden
| |
Collapse
|
3
|
VanBuren W, Feldman M, Shenoy-Bhangle AS, Sakala MD, Young S, Chamie LP, Giudice L, Hindman NM, Tong A, Rabban JT, Yano M, Kilcoyne A, Dave HD, Poder L, Kho RM, Burnett TL, Khan Z, King C, Shen L, Colak C, Burk KS, Andrieu PIC, Franco IVP, Glanc P, Kielar AZ, Taffel MT, Kania LM, Bonde A, Pectasides M, Arif-Tiwari H, Laifer-Narin S, Nicola R, Jha P. Radiology State-of-the-art Review: Endometriosis Imaging Interpretation and Reporting. Radiology 2024; 312:e233482. [PMID: 39287524 DOI: 10.1148/radiol.233482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/19/2024]
Abstract
Endometriosis is a common condition impacting approximately 190 million individuals and up to 50% of women with infertility globally. The disease is characterized by endometrial-like tissue located outside of the uterine corpus, which causes cyclical hemorrhage, inflammation, and fibrosis. Based on clinical suspicion or findings at routine transvaginal pelvic US or other prior imaging, dedicated imaging for endometriosis may be warranted with MRI or advanced transvaginal US. Deep endometriosis (DE) in the pelvis includes evaluation for stromal and fibrotic components and architectural distortion resulting from fibrosis and tethering. It is a disease requiring a compartment-based, pattern-recognition approach. MRI has the benefit of global assessment of the pelvis and is effective in assessing for features of malignancy and for evaluating extrapelvic locations. Transvaginal US has the advantage of dynamic maneuvers to assess for adhesions and may achieve higher spatial resolution for assessing the depth of bowel wall invasion. T1-weighted MRI evaluation increases the specificity of diagnosis by identifying hemorrhagic components, but the presence of T1 signal hyperintensity is not essential for diagnosing DE. Endometriosis is a disease with a broad spectrum; understanding the mild through advanced manifestations, including malignancy evaluation, is within the scope and breadth of radiologists' interpretation.
Collapse
Affiliation(s)
- Wendaline VanBuren
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Myra Feldman
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Anuradha S Shenoy-Bhangle
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Michelle D Sakala
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Scott Young
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Luciana Pardini Chamie
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Linda Giudice
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Nicole M Hindman
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Angela Tong
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Joseph T Rabban
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Motoyo Yano
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Aoife Kilcoyne
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Haatal D Dave
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Liina Poder
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Rosanne M Kho
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Tatnai L Burnett
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Zaraq Khan
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Cara King
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Luyao Shen
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Ceylan Colak
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Kristine S Burk
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Pamela I Causa Andrieu
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Izabela V Pires Franco
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Phyllis Glanc
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Ania Z Kielar
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Myles T Taffel
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Leann M Kania
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Apurva Bonde
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Melina Pectasides
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Hina Arif-Tiwari
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Sherelle Laifer-Narin
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Refky Nicola
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| | - Priyanka Jha
- From the Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55905 (W.V.B., T.L.B., Z.K., C.C., P.I.C.A.); Cleveland Clinic, Cleveland, Ohio (M.F., C.K., M.P.); Massachusetts General Hospital, Harvard Medical School, Boston, Mass (A.S.S.B., A.K.); University of Michigan, Ann Arbor, Mich (M.D.S.); Mayo Clinic Arizona, Phoenix, Ariz (S.Y., M.Y.); Chamie Imagem da Mulher, São Paulo, Brazil (L.P.C.); University of California San Francisco, San Francisco, Calif (L.G., J.T.R., L.P.); NYU Grossman School of Medicine, New York, NY (N.M.H., A.T., M.T.T.); David Geffen School of Medicine, Los Angeles, Calif (H.D.D.); University of Arizona College of Medicine Phoenix/Banner University Medical Center-Phoenix (R.M.K.); Stanford University School of Medicine, Stanford, Calif (L.S.); Brigham and Women's Hospital, Harvard Medical School, Boston, Mass (K.S.B.); Clinic Izabela Pires Franco, Belém, Brazil (I.V.P.F.); Temerty Faculty of Medicine (P.G.), University of Toronto, Toronto, Ontario, Canada (A.Z.K.); Thomas Jefferson University Hospital, Philadelphia, Pa (L.M.K.); University of Texas Health Science Center at San Antonio, San Antonio, Tex (A.B.); University of Arizona College of Medicine, Banner University Medicine, Tucson, Ariz (H.A.T.); Columbia University Irving Medical Center, New York, NY (S.L.N.); SUNY Upstate Medical University, Syracuse, NY (R.N.); and Department of Radiology, Stanford University School of Medicine, Stanford, Calif (P.J.)
| |
Collapse
|
4
|
Perrone U, Ferrero S, Gazzo I, Izzotti A, Leone Roberti Maggiore U, Gustavino C, Ceccaroni M, Bogliolo S, Barra F. Endometrioma surgery: Hit with your best shot (But know when to stop). Best Pract Res Clin Obstet Gynaecol 2024; 96:102528. [PMID: 38977389 DOI: 10.1016/j.bpobgyn.2024.102528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2024] [Revised: 06/08/2024] [Accepted: 06/25/2024] [Indexed: 07/10/2024]
Abstract
Ovarian endometriomas (OEs) are commonly detected by ultrasound in individuals affected by endometriosis. Although surgery was widely regarded in the past as the gold standard for treating OEs, especially in the case of large cysts, the surgical management of OEs remains debated. Firstly, OEs often represent the "tip of the iceberg" of underlying deep endometriosis, and this should be considered when treating OEs to ameliorate patients' pain for focusing on the surgical objectives and providing better patient counseling. In the context of fertility care, OEs may have a detrimental effect on ovarian reserve through structural alterations, inflammatory responses, and oocyte reserve depletion. Conversely, the surgical approach may exacerbate the decline within the same ovarian reserve. While evidence suggests no improvement in in-vitro fertilization (IVF) outcomes following OE surgery, further studies are needed to understand the impact of OE surgery on spontaneous fertility. Therefore, optimal management of OEs is based on individual patient and fertility characteristics such as the woman's age, length of infertility, results of ovarian reserve tests, and surgical background. Among the available surgical approaches, cystectomy appears advantageous in terms of reduced recurrence rates, and traditionally, bipolar coagulation has been used to achieve hemostasis following this approach. Driven by concerns about the negative impact on ovarian reserve, alternative methods to obtain hemostasis include suturing the cyst bed, and novel methodologies such as CO2 laser and plasma energy have emerged as viable surgical options for OEs. In instances where sonographic OE features are non-reassuring, surgery should be contemplated to obtain tissue for histological diagnosis and rule out eventual ovarian malignancy.
Collapse
Affiliation(s)
- Umberto Perrone
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"-ASL4, Via Gio Batta Ghio 9, 16043, Chiavari, Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy
| | - Simone Ferrero
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy; Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genoa, Italy.
| | - Irene Gazzo
- Department of Reproductive Medicine, Ospedale Evangelico Internazionale, Genoa, Italy
| | - Alberto Izzotti
- Unit of Mutagenesis and Cancer Prevention, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
| | | | - Claudio Gustavino
- Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132, Genoa, Italy
| | - Marcello Ceccaroni
- Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally Invasive Pelvic Surgery, International School of Surgical Anatomy, IRCCS "Sacro Cuore - Don Calabria" Hospital, Negrar di Valpolicella, Verona, Italy
| | - Stefano Bogliolo
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"-ASL4, Via Gio Batta Ghio 9, 16043, Chiavari, Genoa, Italy
| | - Fabio Barra
- Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"-ASL4, Via Gio Batta Ghio 9, 16043, Chiavari, Genoa, Italy; Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy
| |
Collapse
|
5
|
Exacoustos C, Ticconi C, Colombi I, Iorio GG, Vaquero E, Selntigia A, Chiaramonte B, Soreca G, Rizzo G. Type and Location of Adenomyosis in Women with Recurrent Pregnancy Loss: A Transvaginal Ultrasonographic Assessment. Reprod Sci 2024; 31:2447-2457. [PMID: 38619796 PMCID: PMC11289184 DOI: 10.1007/s43032-024-01541-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2023] [Accepted: 04/02/2024] [Indexed: 04/16/2024]
Abstract
The current knowledge on adenomyosis as a risk factor for RPL is very scant. Overall 120 women were included in this retrospective observational study. They were divided in three groups each of which consisted of 40 subjects: Group 1: women with RPL who were diagnosed to have adenomyosis on transvaginal ultrasound (TVS); Group 2: patients with RPL without ultrasonographic findings of adenomyosis; Group 3: patients with ultrasound diagnosis of adenomyosis without RPL and at least one live birth pregnancy. The copresence of endometriosis was also investigated. Among women with RPL, patients with adenomyosis (Group 1) had higher number of pregnancy losses (p = 0.03) and lower age at first pregnancy loss (p = 0.03) than women without adenomyosis (Group 2). Moreover, they had more frequently primary RPL (p = 0.008). Adenomyosis of the inner myometrium was found more frequently (p = 0.04) in patients of Group 1 than in patients of Group 3 in which adenomyosis was mainly in the outer myometrium (p= 0.02). No differences were found in the severity of adenomyosis between these two groups of women. TVS findings for endometriosis were observed more frequently in women with adenomyosis without RPL (Group 3) than in the other two groups of patients. Adenomyosis can be a factor involved in RPL. Differences in adenomyosis localization are associated with different risks for RPL. Patients with RPL should be investigated for the presence of adenomyosis and also for the type and localization of the disease in the different myometrial layers.
Collapse
Affiliation(s)
- Caterina Exacoustos
- Department of Surgical Sciences, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| | - Carlo Ticconi
- Department of Surgical Sciences, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy.
| | - Irene Colombi
- Department of Molecular and Developmental Medicine, Obstetrics and Gynecological Clinic University of Siena, Siena, Italy
| | - Giuseppe Gabriele Iorio
- Department of Neuroscience, Reproductive Science and Odontostomatology, University of Naples 'Federico II', Naples, Italy
| | - Elena Vaquero
- Department of Biomedicine and Prevention, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| | - Aikaterini Selntigia
- Department of Surgical Sciences, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| | - Barbara Chiaramonte
- Department of Biomedicine and Prevention, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| | - Giorgia Soreca
- Department of Surgical Sciences, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| | - Giuseppe Rizzo
- Department of Biomedicine and Prevention, Obstetrics and Gynecological Unit, University of Rome 'Tor Vergata', Rome, Italy
| |
Collapse
|
6
|
Orlov S, Sladkevicius P, Jokubkiene L. Evaluating the development of endometriosis and adenomyosis lesions over time: An ultrasound study of symptomatic women. Acta Obstet Gynecol Scand 2024; 103:1634-1644. [PMID: 38687177 PMCID: PMC11266643 DOI: 10.1111/aogs.14865] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2024] [Revised: 04/15/2024] [Accepted: 04/16/2024] [Indexed: 05/02/2024]
Abstract
INTRODUCTION There is a gap in knowledge regarding development of endometriosis and adenomyosis lesions visible at transvaginal ultrasound. The objectives were to evaluate if women with symptoms suggestive of endometriosis or adenomyosis but normal ultrasound examination develop endometriosis or adenomyosis lesions visible at ultrasound over time and if alterations of symptoms over time are associated with ultrasound findings at follow-up. MATERIAL AND METHODS This was a prospective cohort study of 100 symptomatic women with normal initial ultrasound examination during 2014-2017 who underwent follow-up ultrasound examination in 2022. Symptoms suggestive of endometriosis were assessed using visual analog scale at both examinations and minimal clinically important difference of 10 mm was considered as a significant alteration. An examiner with expertise in advanced ultrasound examination of endometriosis performed transvaginal ultrasound examinations in accordance with the consensus protocol by the International Deep Endometriosis Analysis group. RESULTS At follow-up ultrasound examination of 100 women, 13 (13% [95% CI 7.1-21.2]) had visible endometriosis or adenomyosis lesions, 8 (8% [95% CI 3.5-15.2]) had endometriosis lesions, and 6 (6% [95% CI 2.2-12.6]) had adenomyosis. At follow-up, women with endometriosis or adenomyosis lesions reported lower intensity of dysmenorrhea and chronic pelvic pain compared to women without lesions (48 mm [IQR 16-79] vs. 73 mm [IQR 46-85] and 45 mm [IQR 26-57] vs. 57 mm [IQR 36-75], p = 0.087 and p = 0.026, respectively). None of the women with endometriosis or adenomyosis lesions reported increased intensity of dysmenorrhea at follow-up, compared to 32/86 women (37%) without lesions (p = 0.008). Increased intensity of chronic pelvic pain tended to be less common in women with lesions compared to those without (3/13 [23%] vs. 35/86 [41%], p = 0.223). CONCLUSIONS Our findings suggest that in symptomatic women, endometriosis and adenomyosis lesions visible at ultrasound may develop over time. However, majority of women remain having normal ultrasound examinations despite symptoms. Exacerbation of dysmenorrhea or chronic pelvic pain during follow-up was not associated with the development of endometriosis or adenomyosis lesions visible at ultrasound, suggesting that even women with less severe symptoms might benefit from a follow-up ultrasound when indicated.
Collapse
Affiliation(s)
- Sofie Orlov
- Obstetric, Gynecological and Prenatal Ultrasound Research, Department of Clinical Sciences MalmoLund UniversityMalmoSweden
- Department of Obstetrics and GynecologySkane University HospitalMalmoSweden
- Department of Obstetrics and GynecologyYstad HospitalYstadSweden
| | - Povilas Sladkevicius
- Obstetric, Gynecological and Prenatal Ultrasound Research, Department of Clinical Sciences MalmoLund UniversityMalmoSweden
- Department of Obstetrics and GynecologySkane University HospitalMalmoSweden
| | - Ligita Jokubkiene
- Obstetric, Gynecological and Prenatal Ultrasound Research, Department of Clinical Sciences MalmoLund UniversityMalmoSweden
- Department of Obstetrics and GynecologySkane University HospitalMalmoSweden
| |
Collapse
|
7
|
Metzler JM, Finger L, Burkhardt T, Hodel ME, Manegold-Brauer G, Imboden S, Pape J, Imesch P, Witzel I, Bajka M. Systematic, noninvasive endometriosis diagnosis in transvaginal sonography by the Swiss Society of Ultrasound in Medicine. ULTRASCHALL IN DER MEDIZIN (STUTTGART, GERMANY : 1980) 2024; 45:367-388. [PMID: 38788738 DOI: 10.1055/a-2241-5233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2024]
Abstract
We present a new systematic, comprehensive, checklist-based sonographic assessment of endometriosis in the female true pelvis. Emphasis is placed on practical skills teaching. The newly introduced White Sliding Line (WSL) is the core structure. The WSL separates five compartments (anterior, central, posterior, and lateral right and left) containing dedicated endometriosis signs of mobility and morphology to be checked. This approach relies on the 2016 IDEA Consensus and further developments. It directly connects to the 2021 #ENZIAN Classification Standard. In practice, evaluation follows the proposed checklist in all compartments, judging first sliding mobility between organs and structures in a highly dynamic investigation. A rigorous search for deep endometriosis (DE) is then performed. We treat adhesions due to their great clinical importance and possible, reliable diagnosis by TVS as the fifth endometriosis unit, next to endometrioma, DE, adenomyosis, and superficial endometriosis. Including superficial (peritoneal) endometriosis is a future goal.
Collapse
Affiliation(s)
- Julian Matthias Metzler
- Gynecology, University Hospital Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Switzerland
| | - Leana Finger
- Faculty of Medicine, University of Zurich, Switzerland
| | - Tilo Burkhardt
- Obstetrics, University Hospital Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Switzerland
| | | | | | - Sara Imboden
- Gynecology, Inselspital University Hospital, Bern, Switzerland
- Faculty of Medicine, University of Bern, Switzerland
| | - Janna Pape
- Gynecological Endocrinology and Reproductive Medicine, Inselspital University Hospital, Bern, Switzerland
- Faculty of Medicine, University of Bern, Switzerland
| | - Patrick Imesch
- Gynecology, University Hospital Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Switzerland
| | - Isabell Witzel
- Gynecology, University Hospital Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Switzerland
| | - Michael Bajka
- Gynecology, University Hospital Zurich, Switzerland
- Faculty of Medicine, University of Zurich, Switzerland
| |
Collapse
|
8
|
Patel-Lippmann KK, Wasnik AP, Akin EA, Andreotti RF, Ascher SM, Brook OR, Eskander RN, Feldman MK, Jones LP, Martino MA, Patel MD, Patlas MN, Revzin MA, VanBuren W, Yashar CM, Kang SK. ACR Appropriateness Criteria® Clinically Suspected Adnexal Mass, No Acute Symptoms: 2023 Update. J Am Coll Radiol 2024; 21:S79-S99. [PMID: 38823957 DOI: 10.1016/j.jacr.2024.02.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Accepted: 02/28/2024] [Indexed: 06/03/2024]
Abstract
Asymptomatic adnexal masses are commonly encountered in daily radiology practice. Although the vast majority of these masses are benign, a small subset have a risk of malignancy, which require gynecologic oncology referral for best treatment outcomes. Ultrasound, using a combination of both transabdominal, transvaginal, and duplex Doppler technique can accurately characterize the majority of these lesions. MRI with and without contrast is a useful complementary modality that can help characterize indeterminate lesions and assess the risk of malignancy is those that are suspicious. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision process support the systematic analysis of the medical literature from peer reviewed journals. Established methodology principles such as Grading of Recommendations Assessment, Development, and Evaluation or GRADE are adapted to evaluate the evidence. The RAND/UCLA Appropriateness Method User Manual provides the methodology to determine the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where peer reviewed literature is lacking or equivocal, experts may be the primary evidentiary source available to formulate a recommendation.
Collapse
Affiliation(s)
| | | | - Esma A Akin
- The George Washington University Medical Center, Washington, District of Columbia; Commission on Nuclear Medicine and Molecular Imaging
| | | | - Susan M Ascher
- MedStar Georgetown University Hospital, Washington, District of Columbia
| | - Olga R Brook
- Beth Israel Deaconess Medical Center, Boston, Massachusetts
| | - Ramez N Eskander
- University of California, San Diego, San Diego, California; American College of Obstetricians and Gynecologists
| | | | - Lisa P Jones
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
| | - Martin A Martino
- Ascension St. Vincent's, Jacksonville, Florida; University of South Florida, Tampa, Florida, Gynecologic oncologist
| | | | - Michael N Patlas
- Department of Medical Imaging, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Margarita A Revzin
- Yale University School of Medicine, New Haven, Connecticut; Committee on Emergency Radiology-GSER
| | | | - Catheryn M Yashar
- University of California, San Diego, San Diego, California; Commission on Radiation Oncology
| | - Stella K Kang
- Specialty Chair, New York University Medical Center, New York, New York
| |
Collapse
|
9
|
Alson S, Jokubkiene L, Henic E, Sladkevicius P. Prevalence of adenomyosis features in women scheduled for assisted reproductive treatment, using the Morphological Uterus Sonographic Assessment group definitions. Acta Obstet Gynecol Scand 2024; 103:1142-1152. [PMID: 38410091 PMCID: PMC11103150 DOI: 10.1111/aogs.14812] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 02/04/2024] [Accepted: 02/05/2024] [Indexed: 02/28/2024]
Abstract
INTRODUCTION Studies that use standardized ultrasonographic criteria to diagnose adenomyosis in subfertile women are needed. These would improve the understanding of the disease burden and enable further studies on its impact on fertility and assisted reproductive treatment (ART) outcome. The aim of this study was to determine the prevalence of different features of adenomyosis in women scheduled for their first ART, diagnosed at two (2D) and three-dimensional (3D) transvaginal ultrasonography (TVUS) using the revised Morphological Uterus Sonographic Assessment (MUSA) group definitions. MATERIAL AND METHODS This was a prospective, observational cross-sectional study of subfertile women aged 25 to ≤39 years, that were referred to a university hospital for their first ART between December 2018 and May 2021. Of 1224 eligible women, 1160 women fulfilled the inclusion criteria and consented to participate in the study. All women underwent a systematic 2D and 3D TVUS examination. The primary outcome was the presence of direct and indirect features of adenomyosis, as proposed by the MUSA group. Secondary outcomes were to describe the ultrasonographic characteristics of the different features, as well as any difference in the diagnostics at 2D or 3D TVUS and any association with clinical characteristics such as endometriosis. RESULTS At least one direct or indirect feature of adenomyosis was observed in 272 (23.4%, 95% confidence interval [CI] 21.0-25.9) women. Direct features that are pathognomonic for the disease were observed in 111 (9.6%, 95% CI, 7.9-11.3) women. Direct features were visible only at 3D TVUS in 56 (4.8%, 95% CI 3.6-6.1) women, that is, 56/111 (50.5%) of women with at least one direct adenomyosis feature. Direct features were more common in women with endometriosis (OR 2.8, 95% CI 1.8-4.3). CONCLUSIONS We found than one in 10 women scheduled for ART had direct features of adenomyosis at ultrasound examination. The present study suggests that the use of 3D TVUS is an important complement to 2D in the diagnostics of adenomyosis. Our results may further improve the counseling of women scheduled for ART and enables future studies on the impact of different features of adenomyosis on subfertility, ART results and obstetric outcomes.
Collapse
Affiliation(s)
- Sara Alson
- Department of Clinical Sciences, ObstetricGynecological and Prenatal Ultrasound Research, Lund UniversityMalmöSweden
- Department of Obstetrics and GynecologySkåne University HospitalMalmöSweden
- Reproductive Medicine CenterSkåne University HospitalMalmöSweden
| | - Ligita Jokubkiene
- Department of Clinical Sciences, ObstetricGynecological and Prenatal Ultrasound Research, Lund UniversityMalmöSweden
- Department of Obstetrics and GynecologySkåne University HospitalMalmöSweden
| | - Emir Henic
- Reproductive Medicine CenterSkåne University HospitalMalmöSweden
- Department of Translational MedicineLund UniversityMalmöSweden
| | - Povilas Sladkevicius
- Department of Clinical Sciences, ObstetricGynecological and Prenatal Ultrasound Research, Lund UniversityMalmöSweden
- Department of Obstetrics and GynecologySkåne University HospitalMalmöSweden
| |
Collapse
|
10
|
Capozzi VA, Scarpelli E, dell’Omo S, Rolla M, Pezzani A, Morganelli G, Gaiano M, Ghi T, Berretta R. Atypical Endometriosis: A Comprehensive Systematic Review of Pathological Patterns and Diagnostic Challenges. Biomedicines 2024; 12:1209. [PMID: 38927416 PMCID: PMC11201022 DOI: 10.3390/biomedicines12061209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2024] [Revised: 05/20/2024] [Accepted: 05/27/2024] [Indexed: 06/28/2024] Open
Abstract
Endometriosis is a benign condition affecting women of reproductive age. A potential association with ovarian cancer has been documented. Atypical endometriosis (AE) is characterized by deviations from the typical microscopic appearance of endometriosis, including cytologic and architectural atypia. AE has been recognized as a potential precursor to endometriosis-associated ovarian cancers (EAOC), particularly endometrioid and clear cell subtypes. AE presents challenges in diagnosis due to its diverse clinical and pathological features, often requiring careful histological evaluation for accurate identification. Architectural AE, defined by localized proliferation of crowded glands with atypical epithelium resembling endometrial neoplasia, and cytologic AE, characterized by nuclear atypia within the epithelial lining of endometriotic cysts, are key subtypes. Immunohistochemical and molecular studies have revealed aberrant expression of markers such as Ki67, COX-2, BAF250a, p53, estrogen receptor, progesterone receptor, and IMP-3. Long-term follow-up studies suggest relatively low recurrence and malignant transformation rates among patients with AE, but uncertainties persist regarding its exact malignancy potential and optimal management strategies. Integration of artificial intelligence and shared molecular aberrations between AE and EAOC may enhance diagnostic accuracy. Continuous interdisciplinary collaboration and ongoing research efforts are crucial for a deeper understanding of the relationship between endometriosis and carcinogenesis, ultimately improving patient care and surveillance.
Collapse
Affiliation(s)
| | | | | | - Martino Rolla
- Department of Obstetrics and Gynecology, University Hospital of Parma, 43125 Parma, Italy
| | | | | | | | | | | |
Collapse
|
11
|
Chaggar P, Tellum T, De Braud LV, Solangon SA, Setty T, Jurkovic D. Development of deep pelvic endometriosis following acute haemoperitoneum: a prospective ultrasound study. Hum Reprod Open 2024; 2024:hoae036. [PMID: 38905001 PMCID: PMC11189661 DOI: 10.1093/hropen/hoae036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2024] [Revised: 03/07/2024] [Indexed: 06/23/2024] Open
Abstract
STUDY QUESTION Is acute haemoperitoneum that is managed conservatively a precursor of deep endometriosis? SUMMARY ANSWER Our study provides evidence to suggest that acute haemoperitoneum may lead to the development of deep endometriosis in a significant proportion of cases. WHAT IS KNOWN ALREADY A recent pilot study was the first to suggest that acute haemoperitoneum could be a precursor of deep endometriosis. However, the sample size was small, and the follow-up was not standardized owing to unknown rates of clot absorption and development of endometriosis. STUDY DESIGN SIZE DURATION This was a prospective observational cohort study conducted at a single centre over a 31-month period. A required sample size of 30 was calculated using results from a previous study, with a minimum of 15 women each in the groups with and without significant haemoperitoneum (study and control groups, respectively). A total of 59 women were recruited to the study and eight were lost to follow-up. The final sample comprised 51 women, 15 in the study group and 36 in the control group. PARTICIPANTS/MATERIALS SETTING METHODS All non-pregnant, premenopausal women aged 18-50 years who consecutively presented to our dedicated gynaecological diagnostic unit with severe acute lower abdominal pain were eligible for this study. We only included women who were clinically stable and were suitable for conservative management. Those with prior history or evidence of endometriosis on their initial ultrasound scan, previous hysterectomy, or bilateral oophorectomy were excluded. Participants had standardized follow-up visits for 6 months, with pelvic ultrasound scans and the British Society of Gynaecological Endoscopy pelvic pain questionnaires completed at each visit. The primary outcome was the sonographically confirmed presence of newly formed endometriosis. Secondary outcomes were the presence and change of pelvic pain symptoms and health-related quality of life (HR-QOL). MAIN RESULTS AND THE ROLE OF CHANCE After completion of follow-up, 7/15 (47%; 95% CI 21.3-71.4%) women presenting with acute haemoperitoneum (study group) developed sonographic evidence of deep endometriosis, compared to 0/36 (0%; 97.5% CI 0.0-9.7%) women in the control group. A ruptured functional haemorrhagic cyst was the most common cause of haemoperitoneum, occurring in 13/15 cases (87%). The time from the initial event to sonographic evidence of endometriosis varied from 2 to 6 months. The EuroQol visual analogue scores were not significantly different at baseline between the groups that developed and did not develop endometriosis [28 (interquartile range (IQR) 15-40, n = 6) vs 56 (IQR 35-75, n = 44), P = 0.09], while the EuroQol-5D values were lower in the endometriosis group [-0.01 (IQR -0.07 to 0.19, n = 6) vs 0.62 (IQR 0.24-0.73, n = 44), P = 0.002]. At 6 months, the EuroQol-5D scores were improved in both groups, but remained significantly lower in the endometriosis group compared to the no endometriosis group [0.69 (IQR 0.66-0.80, n = 6) vs 0.85 (IQR 0.76-1.00, n = 44), P = 0.03]. There was no clinically relevant difference in the pelvic pain scores at either time point. LIMITATIONS REASONS FOR CAUTION It remains uncertain whether minimal, superficial endometriosis existed at commencement of the study and had a role in the development of deep endometriosis. Although the ultrasound findings were in keeping with deep endometriosis, this was not confirmed histologically. The pelvic pain and HR-QOL findings could have been influenced by the baseline scores being taken when the patient was admitted with acute pain. Also, the sample size was too small to draw reliable conclusions regarding the impact of newly developed endometriosis on QoL. WIDER IMPLICATIONS OF THE FINDINGS Our study provides further evidence showing that significant haemoperitoneum may be a precursor of deep endometriosis. Haemodynamically stable women presenting with acute pelvic pain and significant haemoperitoneum should be counselled about the risk of developing deep endometriosis. Interventional studies should be carried out in the future to see whether laparoscopy and pelvic washout could prevent development of deep endometriosis. Preventative strategies, including treatment to suppress ovulation and formation of functional cysts, should be further investigated. This includes the combined and progesterone-only contraceptive pills. Larger future studies are also required to assess women over a longer period of time, with adjustment for confounding factors, to evaluate a possible effect on HR-QOL and pain symptoms. STUDY FUNDING/COMPETING INTERESTS Funding was obtained from The Gynaecology Ultrasound Centre, London, UK. TT received personal fees from GE, Samsung, Medtronic, and Merck for lectures on ultrasound. TT also received a postdoctoral grant from the South-Eastern Norwegian Health Authority (grant number 2020083). TRIAL REGISTRATION NUMBER researchregistry6472.
Collapse
Affiliation(s)
- Prubpreet Chaggar
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
| | - Tina Tellum
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
- Department of Gynaecology, Oslo University Hospital, Oslo, Norway
| | - Lucrezia Viola De Braud
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
| | - Sarah Annie Solangon
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
| | - Thulasi Setty
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
| | - Davor Jurkovic
- EGA Institute for Women's Health, Faculty of Population and Health Sciences, University College Hospital, London, UK
| |
Collapse
|
12
|
Alson S, Henic E, Jokubkiene L, Sladkevicius P. Endometriosis diagnosed by ultrasound is associated with lower live birth rates in women undergoing their first in vitro fertilization/intracytoplasmic sperm injection treatment. Fertil Steril 2024; 121:832-841. [PMID: 38246403 DOI: 10.1016/j.fertnstert.2024.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2023] [Revised: 01/09/2024] [Accepted: 01/15/2024] [Indexed: 01/23/2024]
Abstract
OBJECTIVE To study the cumulative live birth rate (CLBR) after the first in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) treatment in women with or without deep-infiltrating endometriosis (DIE) and/or endometrioma diagnosed by transvaginal ultrasonography (TVUS), using the International Deep Endometriosis Analysis (IDEA) group definitions. DESIGN Prospective observational cohort study at a university hospital. PATIENTS(S) In total, 1,040 women with subfertility aged 25 to ≤39 years were undergoing their first IVF/ICSI treatment between January 2019 and October 2022. Of these, 234 (22.5%; 95% confidence interval [CI], 20.0-25.0) women were diagnosed with DIE and/or endometrioma at systematic TVUS before starting their treatment. INTERVENTION(S) All women underwent their first IVF or ICSI treatment. Fresh and/or frozen embryos from the first cycle were used until pregnancy was achieved or no embryos remained. MAIN OUTCOME MEASURE(S) Cumulative live birth rate after the first IVF/ICSI cycle in women with or without DIE and/or endometrioma. RESULT(S) The CLBR after the first IVF/ICSI treatment in the total cohort of women was 426/1,040 (41.0%; 95% CI, 38.0-44.0). Women with DIE and/or endometrioma had a lower CLBR (78/234, 33.3%; 95% CI, 27.3-39.4) than women without the disease (348/806, 43.2%; 95% CI, 39.8-46.6). The crude relative risk (RR) for cumulative live birth for women with DIE and/or endometrioma was 0.77; 95% CI, 0.63-0.94, and after adjustments were made for age, body mass index, s-antimüllerian hormone, stimulation protocol, and day for embryo transfer, the adjusted RR was 0.63; 95% CI, 0.48-0.82. There was no difference in the number of retrieved mature oocytes, fertilization rate, or good quality embryos between the 2 groups. CONCLUSION The presence of DIE and/or endometrioma diagnosed by TVUS lowers the chance of live birth in women undergoing their first IVF/ICSI treatment.
Collapse
Affiliation(s)
- Sara Alson
- Obstetric, Gynecological and Prenatal Ultrasound research, Department of Clinical Sciences, Malmö, Lund University, Sweden; Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden; Reproductive Medicine Center, Skåne University Hospital, Malmö, Sweden.
| | - Emir Henic
- Reproductive Medicine Center, Skåne University Hospital, Malmö, Sweden; Department of Translational Medicine, Lund University, Malmö, Sweden
| | - Ligita Jokubkiene
- Obstetric, Gynecological and Prenatal Ultrasound research, Department of Clinical Sciences, Malmö, Lund University, Sweden; Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden
| | - Povilas Sladkevicius
- Obstetric, Gynecological and Prenatal Ultrasound research, Department of Clinical Sciences, Malmö, Lund University, Sweden; Department of Obstetrics and Gynecology, Skåne University Hospital, Malmö, Sweden
| |
Collapse
|
13
|
Vanni G, Selntigia A, Marsella VE, Russo C, Pellicciaro M, Materazzo M, Rizzo G, Buonomo OC, Exacoustos C. Breast Cancer in Patients with Previous Endometriosis Showed Low Aggressive Subtype. MEDICINA (KAUNAS, LITHUANIA) 2024; 60:625. [PMID: 38674271 PMCID: PMC11051959 DOI: 10.3390/medicina60040625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/09/2024] [Revised: 03/31/2024] [Accepted: 04/04/2024] [Indexed: 04/28/2024]
Abstract
Background and Objectives: The association between endometriosis and breast cancer still remains controversial. The aim of this study was to investigate the different subtypes of breast cancer, immunohistochemical markers, hormone receptors, and ki67 proliferation indexes in patients with and without endometriosis and/or adenomyosis. Materials and Methods: All patients with endometriosis and breast cancer were enrolled. Women with endometriosis and breast cancer (Group BC+EN+) were compared to patients with breast cancer without endometriosis (group BC+EN-) and those with endometriosis without breast cancer (group BC-EN+). General population characteristics and histological and immunohistochemical subtypes of breast cancer were compared between groups. Results: Our study included 41 cases affected by both endometriosis and/or adenomyosis and breast cancer (Group BC+EN+) that were matched (1:2) with 82 patients affected only by breast cancer (group BC+EN-) and 82 patients affected only by endometriosis and/or adenomyosis (group BC-EN+). Group BC+EN+ presented a higher percentage of ER receptor expression (83% vs. 70%, p = 0.02), as well as lower values of Ki 67% (15% vs. 24%, p < 0.0001) and HER2+ (9.8% vs. 28%, p = 0.022). These findings were more evident when comparing patients with premenopausal status, while in postmenopausal patients, this difference was no longer significant. Regarding endometriosis, no statistical differences were observed in type or specific localization of the disease among the groups with and without breast cancer. Conclusions: Patients with endometriosis presented lower aggressive breast cancer rates with higher values of ER% and lower values of Ki 67 and HER2neu+. The type and severity of endometriotic diseases seemed not to influence breast cancer occurrence.
Collapse
Affiliation(s)
- Gianluca Vanni
- Breast Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (G.V.); (M.P.); (M.M.); (O.C.B.)
| | - Aikaterini Selntigia
- Obstetrics and Gynecological Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (A.S.); (C.R.); (C.E.)
| | - Valentina Enrica Marsella
- Breast Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (G.V.); (M.P.); (M.M.); (O.C.B.)
| | - Consuelo Russo
- Obstetrics and Gynecological Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (A.S.); (C.R.); (C.E.)
- Ph.D. Program in Translation Medicine, Department Biomedicine and Prevention, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
| | - Marco Pellicciaro
- Breast Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (G.V.); (M.P.); (M.M.); (O.C.B.)
- Ph.D. Program in Applied Medical-Surgical Sciences, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
| | - Marco Materazzo
- Breast Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (G.V.); (M.P.); (M.M.); (O.C.B.)
- Ph.D. Program in Applied Medical-Surgical Sciences, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy
| | - Giuseppe Rizzo
- Obstetrics and Gynecological Unit, Department Biomedicine and Prevention, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy;
| | - Oreste Claudio Buonomo
- Breast Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (G.V.); (M.P.); (M.M.); (O.C.B.)
- General Surgery Program, UNIBAS, University of Basilicata, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy
| | - Caterina Exacoustos
- Obstetrics and Gynecological Unit, Department of Surgical Science, University of Rome “Tor Vergata”, Viale Oxford 81, 00133 Rome, Italy; (A.S.); (C.R.); (C.E.)
| |
Collapse
|
14
|
Liu L, Cai W, Zhou C, Tian H, Wu B, Zhang J, Yue G, Hao Y. Ultrasound radiomics-based artificial intelligence model to assist in the differential diagnosis of ovarian endometrioma and ovarian dermoid cyst. Front Med (Lausanne) 2024; 11:1362588. [PMID: 38523908 PMCID: PMC10957533 DOI: 10.3389/fmed.2024.1362588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Accepted: 02/27/2024] [Indexed: 03/26/2024] Open
Abstract
Background Accurately differentiating between ovarian endometrioma and ovarian dermoid cyst is of clinical significance. However, the ultrasound appearance of these two diseases is variable, occasionally causing confusion and overlap with each other. This study aimed to develop a diagnostic classification model based on ultrasound radiomics to intelligently distinguish and diagnose the two diseases. Methods We collected ovarian ultrasound images from participants diagnosed as patients with ovarian endometrioma or ovarian dermoid cyst. Feature extraction and selection were performed using the Mann-Whitney U-test, Spearman correlation analysis, and the least absolute shrinkage and selection operator (LASSO) regression. We then input the final features into the machine learning classifiers for model construction. A nomogram was established by combining the radiomic signature and clinical signature. Results A total of 407 participants with 407 lesions were included and categorized into the ovarian endometriomas group (n = 200) and the dermoid cyst group (n = 207). In the test cohort, Logistic Regression (LR) achieved the highest area under curve (AUC) value (0.981, 95% CI: 0.963-1.000), the highest accuracy (94.8%), and the highest sensitivity (95.5%), while LightGBM achieved the highest specificity (97.1%). A nomogram incorporating both clinical features and radiomic features achieved the highest level of performance (AUC: 0.987, 95% CI: 0.967-1.000, accuracy: 95.1%, sensitivity: 88.0%, specificity: 100.0%, PPV: 100.0%, NPV: 88.0%, precision: 93.6%). No statistical difference in diagnostic performance was observed between the radiomic model and the nomogram (P > 0.05). The diagnostic indexes of radiomic model were comparable to that of senior radiologists and superior to that of junior radiologist. The diagnostic performance of junior radiologists significantly improved with the assistance of the model. Conclusion This ultrasound radiomics-based model demonstrated superior diagnostic performance compared to those of junior radiologists and comparable diagnostic performance to those of senior radiologists, and it has the potential to enhance the diagnostic performance of junior radiologists.
Collapse
Affiliation(s)
- Lu Liu
- Department of Ultrasound Medicine, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Wenjun Cai
- Department of Ultrasound, Shenzhen University General Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Chenyang Zhou
- Department of Information, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Hongyan Tian
- Department of Ultrasound Medicine, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Beibei Wu
- Department of Ultrasound Medicine, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Jing Zhang
- Department of Ultrasound Medicine, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Guanghui Yue
- National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, School of Biomedical Engineering, Shenzhen University Medical School, Shenzhen University, Shenzhen, P. R. China
| | - Yi Hao
- Department of Ultrasound Medicine, South China Hospital, Medical School, Shenzhen University, Shenzhen, P. R. China
| |
Collapse
|
15
|
Avery JC, Deslandes A, Freger SM, Leonardi M, Lo G, Carneiro G, Condous G, Hull ML. Noninvasive diagnostic imaging for endometriosis part 1: a systematic review of recent developments in ultrasound, combination imaging, and artificial intelligence. Fertil Steril 2024; 121:164-188. [PMID: 38101562 DOI: 10.1016/j.fertnstert.2023.12.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2023] [Accepted: 12/06/2023] [Indexed: 12/17/2023]
Abstract
Endometriosis affects 1 in 9 women and those assigned female at birth. However, it takes 6.4 years to diagnose using the conventional standard of laparoscopy. Noninvasive imaging enables a timelier diagnosis, reducing diagnostic delay as well as the risk and expense of surgery. This review updates the exponentially increasing literature exploring the diagnostic value of endometriosis specialist transvaginal ultrasound (eTVUS), combinations of eTVUS and specialist magnetic resonance imaging, and artificial intelligence. Concentrating on literature that emerged after the publication of the IDEA consensus in 2016, we identified 6192 publications and reviewed 49 studies focused on diagnosing endometriosis using emerging imaging techniques. The diagnostic performance of eTVUS continues to improve but there are still limitations. eTVUS reliably detects ovarian endometriomas, shows high specificity for deep endometriosis and should be considered diagnostic. However, a negative scan cannot preclude endometriosis as eTVUS shows moderate sensitivity scores for deep endometriosis, with the sonographic evaluation of superficial endometriosis still in its infancy. The fast-growing area of artificial intelligence in endometriosis detection is still evolving, but shows great promise, particularly in the area of combined multimodal techniques. We finalize our commentary by exploring the implications of practice change for surgeons, sonographers, radiologists, and fertility specialists. Direct benefits for endometriosis patients include reduced diagnostic delay, better access to targeted therapeutics, higher quality operative procedures, and improved fertility treatment plans.
Collapse
Affiliation(s)
- Jodie C Avery
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia.
| | - Alison Deslandes
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia
| | - Shay M Freger
- Department of Obstetrics and Gynecology McMaster University, Hamilton, ON, Canada
| | - Mathew Leonardi
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Department of Obstetrics and Gynecology McMaster University, Hamilton, ON, Canada
| | - Glen Lo
- Curtin Medical School, Curtin University, Perth, Western Australia, Australia
| | - Gustavo Carneiro
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Centre for Vision, Speech and Signal Processing (CVSSP), School of Computer Science and Electronic Engineering, University of Surrey, Guildford, United Kingdom
| | - G Condous
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Gynaecology Department, Omni Ultrasound and Gynaecological Care, Sydney, New South Wales, Australia
| | - Mary Louise Hull
- Robinson Research Institute, Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia; Gynaecology Department, Embrace Fertility, Adelaide, South Australia, Australia
| |
Collapse
|
16
|
Eberle A, Nguyen DB, Smith JP, Mansour FW, Krishnamurthy S, Zakhari A. Medical Management of Ovarian Endometriomas: A Systematic Review and Meta-analysis. Obstet Gynecol 2024; 143:53-66. [PMID: 37944155 DOI: 10.1097/aog.0000000000005444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2023] [Accepted: 09/21/2023] [Indexed: 11/12/2023]
Abstract
OBJECTIVE To estimate the effect of medical management on the size of ovarian endometriomas. DATA SOURCE Online databases were searched from inception to October 2022, including Ovid MEDLINE, Ovid EMBASE, PubMed, EBM Reviews-Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov , and Web of Science. METHODS OF STUDY SELECTION Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, we included all English-language, full-text articles that reported on change in endometrioma size (either diameter or volume) after medical interventions. Studies evaluating surgical interventions or postoperative recurrence were excluded. All screening and data extraction were performed independently by two authors. Risk of bias assessment was performed with either the Cochrane Risk of Bias Tool for randomized controlled trials or a modified Newcastle-Ottawa Scale for observational studies. TABULATION, INTEGRATION, AND RESULTS After removal of duplicates, 9,332 studies were screened, with 33 full-text articles deemed eligible for inclusion. In the meta-analysis, dienogest showed significant reduction in cyst diameter (reduction 1.32 cm, 95% CI, 0.91-1.73, eight studies, n=418 cysts) and volume (mean difference of log-transformed volume 1.35, 95% CI, 0.87-1.83, seven studies, n=282 cysts). Similarly, significant reductions were seen with the oral contraceptive pill (OCP) (1.06 cm, 95% CI, 0.59-1.53, nine studies, n=455), gonadotropin-releasing hormone (GnRH) agonists (1.17 cm, 95% CI, 0.42-1.92, four studies, n=128 cysts), norethindrone acetate (0.6 cm, 95% CI, 0.27-0.94, two studies, n=88 cysts), and danazol (1.95 cm, 95% CI, 1.18-2.73, two studies, n=34 cysts). Norethindrone acetate with aromatase inhibitor was also effective in reducing endometrioma volume (mean difference of log-transformed volume 1.47, 95% CI, 0.16-2.78, two studies, n=34 cysts). CONCLUSION Medical management with dienogest, OCPs, GnRH agonists, norethindrone acetate, norethindrone acetate with aromatase inhibitor, or danazol can reduce the size of ovarian endometriomas. SYSTEMATIC REVIEW REGISTRATION PROSPERO, CRD 42022363319.
Collapse
Affiliation(s)
- Alexa Eberle
- Department of Obstetrics and Gynecology, McGill University Health Centre, Montreal, Quebec, Canada
| | | | | | | | | | | |
Collapse
|
17
|
Nadă ES, Coroleucă CB, Coroleucă CA, Brătilă E. Ovarian Stimulation for In Vitro Fertilization and Reproductive Outcome after Surgical Treatment of Endometriosis Compared with Tubal Factor Infertility. Clin Pract 2023; 14:1-12. [PMID: 38391397 PMCID: PMC10887715 DOI: 10.3390/clinpract14010001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 12/15/2023] [Accepted: 12/18/2023] [Indexed: 02/24/2024] Open
Abstract
Endometriosis is a common cause of infertility among reproductive-age women. A low ovarian reserve is associated with the presence of endometriotic cysts, and this is accentuated even more after surgery. Patients with a history of endometrioma are a special category of poor ovarian reserve requiring in vitro fertilization (IVF). The aim of this retrospective study was to evaluate the characteristics and outcome of ovarian stimulation and embryo transfer in women with a history of ovarian surgery for endometrioma compared with a control group with tubal factor infertility. A total of 146 patients had previous laparoscopic cystectomy for endometrioma (group A) and their IVF results were compared with 136 patients with documented tubal obstruction (group B). In both groups, the most frequently used ovarian stimulation protocol was the short antagonist in 84.24% versus 80.88%. The number of stimulation days was between 6 and 15 days in the two groups with a mean value of 12.76 days in group A and 9.47 days in group B. The clinical pregnancy rate was 26.77% in the endometrioma group and 39.68% in the tubal obstruction group. Patients with a history of endometrioma are less likely to conceive than those with tubal obstruction despite having similar ovarian reserve and stimulation results.
Collapse
Affiliation(s)
- Elena-Silvia Nadă
- Department of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Department of Obstetrics and Gynecology, "Prof. Dr. Panait Sîrbu" Clinical Hospital of Obstetrics and Gynecology, 060251 Bucharest, Romania
| | - Cătălin Bogdan Coroleucă
- Department of Obstetrics and Gynecology, "Prof. Dr. Panait Sîrbu" Clinical Hospital of Obstetrics and Gynecology, 060251 Bucharest, Romania
| | - Ciprian Andrei Coroleucă
- Department of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Department of Obstetrics and Gynecology, "Prof. Dr. Panait Sîrbu" Clinical Hospital of Obstetrics and Gynecology, 060251 Bucharest, Romania
| | - Elvira Brătilă
- Department of Obstetrics and Gynecology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania
- Department of Obstetrics and Gynecology, "Prof. Dr. Panait Sîrbu" Clinical Hospital of Obstetrics and Gynecology, 060251 Bucharest, Romania
| |
Collapse
|
18
|
Knez J, Bean E, Nijjar S, Tellum T, Chaggar P, Jurkovic D. Natural progression of deep pelvic endometriosis in women who opt for expectant management. Acta Obstet Gynecol Scand 2023; 102:1298-1305. [PMID: 37190782 PMCID: PMC10540915 DOI: 10.1111/aogs.14491] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 11/09/2022] [Accepted: 11/20/2022] [Indexed: 05/17/2023]
Abstract
INTRODUCTION The natural history of endometriosis is poorly understood, and despite numerous studies, the rate of the disease progression and optimal treatment planning in women who are asymptomatic or experience mild symptoms not requiring treatment are unknown. The aim of this study was to assess the behavior of deep endometriosis in women who are managed expectantly without any medical or surgical intervention. MATERIAL AND METHODS A retrospective cohort study of women diagnosed with deep endometriosis on transvaginal ultrasound scan at the Department of Gynecology, University College London Hospitals and The Gynecology Ultrasound Centre, London, UK, from April 2007 to April 2022. All women attended for at least two ultrasound scans which were carried out by a single expert ultrasound examiner and at least 6 months apart. The number and position of endometriotic nodules were recorded, and the mean diameter of each nodule was calculated from measurements taken in three orthogonal planes. RESULTS During the study period, 1922 women were found to have moderate or severe deep endometriosis on pelvic ultrasound examination. A total of 135 premenopausal women who were managed expectantly fitted the inclusion criteria. The median number of endometriotic nodules per woman at the initial visit was 2 (range: 0-7), and the median follow-up time was 666 days (181-2984). In the follow-up period, 50/135 women (37%, 95% CI: 29-46) developed additional nodules or experienced an increase in nodule size, and 17/135 women (13%, 95% CI: 8-19) had a regression in the number or size of the nodules. In the remaining 68/135 women (50%, 95% CI: 42-59) the disease remained static during the follow-up. The median change in mean diameter of nodules during the study period per woman was +0.13 mm (-11.67 - +5.83), with an annual growth rate of +0.09 mm/year (-6.65 - +6.45). CONCLUSIONS In our study we found evidence of deep endometriosis progression in just over a third of women. In view of this, asymptomatic or mildly symptomatic women diagnosed with deep endometriosis could be reassured that their disease is unlikely to worsen with time.
Collapse
Affiliation(s)
- Jure Knez
- Department of Women's HealthUniversity College London HospitalLondonUK
- Clinic for GynecologyUniversity Medical Centre MariborMariborSlovenia
| | - Elisabeth Bean
- Department of Women's HealthUniversity College London HospitalLondonUK
| | - Simrit Nijjar
- Department of Women's HealthUniversity College London HospitalLondonUK
| | - Tina Tellum
- Department of Women's HealthUniversity College London HospitalLondonUK
- Department of GynecologyOslo University HospitalOsloNorway
| | - Prubpreet Chaggar
- Department of Women's HealthUniversity College London HospitalLondonUK
| | - Davor Jurkovic
- Department of Women's HealthUniversity College London HospitalLondonUK
- The Gynaecology Ultrasound CentreLondonUK
| |
Collapse
|
19
|
Chaggar P, Tellum T, Thanatsis N, De Braud LV, Setty T, Jurkovic D. Prevalence of deep and ovarian endometriosis in women attending a general gynecology clinic: prospective cohort study. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2023; 61:632-641. [PMID: 36776112 DOI: 10.1002/uog.26175] [Citation(s) in RCA: 10] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/28/2022] [Accepted: 01/23/2023] [Indexed: 05/04/2023]
Abstract
OBJECTIVES To assess using transvaginal ultrasound the prevalence of deep and ovarian endometriosis in premenopausal women attending a general gynecology clinic. We also investigated whether the presence of endometriosis was associated with various demographic factors and other pelvic abnormalities. METHODS This was a prospective observational cohort study carried out between February 2019 and October 2020. Consecutive premenopausal women who attended our general gynecology clinic underwent pelvic ultrasound examination, performed by a single experienced operator. Pregnant women and those with a history of hysterectomy or oophorectomy were excluded. The primary outcome was the prevalence of deep and/or ovarian endometriosis. Secondary outcomes were the anatomical distribution of endometriotic lesions and the association of endometriosis with demographic characteristics and various pelvic abnormalities, which were analyzed using logistic regression and multivariable analysis. RESULTS A total of 1026 women were included in the final study sample, of whom 194 (18.9% (95% CI, 16.6-21.4%)) had sonographic evidence of deep and/or ovarian endometriosis. Of the 194 women diagnosed with endometriosis, 106 (54.6% (95% CI, 47.4-61.8%)) were diagnosed with endometriotic nodules only, 26 (13.4% (95% CI, 9.0-19.0%)) with ovarian endometriomas only, and 62 (32.0% (95% CI, 25.5-39.0%)) women had evidence of both. There was a total of 348 endometriotic nodules in 168 women, located most frequently in the retrocervical area (166/348; 47.7% (95% CI, 42.4-53.1%)), uterosacral ligaments (96/348; 27.6% (95% CI, 23.0-32.6%)) and bowel (40/348; 11.5% (95% CI, 8.3-15.3%)). Multivariable analysis found significant positive associations between endometriosis and both adenomyosis (odds ratio (OR), 1.72 (95% CI, 1.10-2.69); P = 0.02) and pelvic adhesions (OR, 25.7 (95% CI, 16.7-39.3); P < 0.001), whilst higher parity (OR, 0.44 (95% CI, 0.24-0.81); P = 0.03) and history of Cesarean section (OR, 0.18 (95% CI, 0.06-0.52); P = 0.002) were associated with a lower occurrence of endometriosis. A total of 75/1026 women (7.3% (95% CI, 5.8-9.1%)) underwent laparoscopy within 6 months of pelvic ultrasound examination. There was very good agreement between ultrasound and surgical findings, with a kappa value of 0.84 (95% CI, 0.69-0.99). CONCLUSIONS Deep and/or ovarian endometriosis was present in nearly one in five women attending a general gynecology clinic. There were significant positive associations with adenomyosis and pelvic adhesions and negative associations with higher parity and previous Cesarean section. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- P Chaggar
- Institute for Women's Health, University College Hospital, London, UK
| | - T Tellum
- Institute for Women's Health, University College Hospital, London, UK
- Department of Gynaecology, Oslo University Hospital, Oslo, Norway
| | - N Thanatsis
- Institute for Women's Health, University College Hospital, London, UK
| | - L V De Braud
- Institute for Women's Health, University College Hospital, London, UK
| | - T Setty
- Institute for Women's Health, University College Hospital, London, UK
| | - D Jurkovic
- Institute for Women's Health, University College Hospital, London, UK
| |
Collapse
|
20
|
Diagnostic Accuracy of Transvaginal Sonography for Deeply Infiltrating Endometriosis and Pouch of Douglas Obliteration in the Presence or Absence of Ovarian Endometrioma. IRANIAN JOURNAL OF RADIOLOGY 2023. [DOI: 10.5812/iranjradiol-127068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Background: Endometriosis is one of the most common gynecological diseases worldwide. Significant attention has been drawn to this multiorgan and often painful disorder. Objectives: This study aimed to examine the accuracy of transvaginal sonography (TVS) in the diagnosis of deeply infiltrating endometriosis (DIE) with respect to the presence or absence of ovarian endometrioma (OE). Patients and Methods: This cross-sectional study was performed on all patients undergoing TVS before gynecological laparoscopy. With pathological confirmation as the standard reference, the diagnostic accuracy of TVS for DIE and pouch of Douglas (POD) obliteration was compared with that of laparoscopy in the anterior and posterior pelvic compartments with respect to the presence or absence of OE. Agreement between TVS and laparoscopy was evaluated for each case, and Cohen’s kappa statistic was measured for each site of involvement. Moreover, sensitivity, specificity, negative and positive predictive values, and likelihood ratios of TVS were calculated, with laparoscopy as the reference test. Results: A total of 110 patients, with a mean age of 37.20 ± 7.16 years, were recruited in this study. The accuracy, sensitivity, and negative predictive value of TVS for the diagnosis of DIE and POD obliteration were estimated at 89.5%, 58.3%, and 88.9% in the anterior pelvic compartment and 93.3%, 92%, and 70.6% in the posterior pelvic compartment, respectively. Nevertheless, TVS showed lower sensitivity for detecting pelvic adhesions and peritoneal cysts compared to laparoscopy. The presence of OE did not significantly increase the accuracy of TVS for the diagnosis of DIE or POD obliteration (P > 0.05). Conclusion: The present study showed that TVS is an adequately accurate and non-invasive diagnostic tool for the detection and mapping of DIE and POD obliteration, regardless of the presence of OE. TVS may waive the need for exploratory laparoscopy in DIE or at least facilitate precise pre-procedural DIE mapping.
Collapse
|
21
|
Mirzaei N, Jahanian Sadatmahalleh S, Rouholamin S, Nasiri M. A randomized trial assessing the efficacy of Silymarin on endometrioma-related manifestations. Sci Rep 2022; 12:17549. [PMID: 36266431 PMCID: PMC9584967 DOI: 10.1038/s41598-022-22073-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Accepted: 10/10/2022] [Indexed: 01/13/2023] Open
Abstract
To study the effect of silymarin on the Interleukin-6 (IL-6) level, size of endometrioma lesion, pain, sexual function, and Quality of Life (QoL) in women diagnosed with endometriosis. This randomized, double-blind placebo-controlled clinical trial was performed on 70 women with endometriosis which was divided into two groups of intervention and control. The intervention was 140 mg silymarin (or matching placebo) administered twice daily for 12 weeks. The volume of endometrioma lesions, the level of IL-6 concentration in serum, pain, sexual function, and QoL were analyzed before and after the intervention. The means of endometrioma volume (P = 0.04), IL-6 (P = 0.002), and pain (P < 0.001) were reduced significantly in the silymarin group after intervention. However, the QoL and female sexual function did not improve substantially in the two groups (P > 0.05). Silymarin significantly reduced interleukin-6 levels, sizes of endometrioma lesions, and pain-related symptoms. The trial has been registered in the Iranian Registry of Clinical Trials (IRCT20150905023897N5) on 4th February 2020 (04/02/2020) ( https://en.irct.ir/trial/42215 ) and the date of initial participant enrollment was 2nd March 2020 (02/03/2020).
Collapse
Affiliation(s)
- Negin Mirzaei
- grid.412266.50000 0001 1781 3962Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Jalal Al-Ahmad Highway, Nasr Bridge, Tehran, 14115-111 Iran
| | - Shahideh Jahanian Sadatmahalleh
- grid.412266.50000 0001 1781 3962Department of Reproductive Health and Midwifery, Faculty of Medical Sciences, Tarbiat Modares University, Jalal Al-Ahmad Highway, Nasr Bridge, Tehran, 14115-111 Iran
| | - Safoura Rouholamin
- grid.411036.10000 0001 1498 685XDepartment of Obstetrics and Gynecology, Faculty of Medical Sciences, Isfahan University of Medical Sciences, Hezar-Jerib Ave., Isfahan, 81746 73461 Iran
| | - Malihe Nasiri
- grid.411600.2Department of Basic Sciences, Faculty of Nursing and Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
22
|
Gu Z, Li X, Shi J, Wu Y, Zhang J, Zhang C, Yan H, Leng J. The Development of Predictive Nomogram of Recurrence for Patients With Endometrioma After Cystectomy Who Were Younger Than 45 Years Old and Received Postoperative Therapy. Front Med (Lausanne) 2022; 9:872481. [PMID: 35755050 PMCID: PMC9218256 DOI: 10.3389/fmed.2022.872481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2022] [Accepted: 05/06/2022] [Indexed: 11/29/2022] Open
Abstract
Objective: This study aimed to establish an effective prognostic nomogram for the postoperative recurrence of endometrioma or endometriosis-related pain for patients with endometrioma after long-term follow-up, who were younger than 45 years old and received postoperative therapy. Methods The predictive nomogram was based on 323 patients who underwent cystectomy for endometrioma at Perking Union Medical College Hospital from January 2009 to April 2013, and the last follow-up occurred in September 2018. We collected information on all included patients, including preoperative data, intraoperative data, and long-term follow-up data after surgery. The Cox proportional hazards regression model was used to evaluate the prognostic effects of multiple clinical parameters on recurrence. The survival curve was depicted based on Kaplan-Meier method and compared by log-rank method. The Index of concordance (C-index) and calibration curves were used to access the discrimination ability and predictive accuracy of the nomogram respectively, and the results were further validated via bootstrap resampling. In addition, calculating the area under the curve (AUC) via risk scores of patients aimed to further access the prediction ability of the model. Results On multivariate analysis of derivation cohort, independent factors for recurrence such as dysmenorrhea degree, sum of both cyst diameters, presence of adenomyosis, and other essential factors for recurrence such as age at surgery, presence of uterine fibroids were all selected into the nomogram. The C-index of the nomogram for predicting recurrence was 0.683 (95% CI, 0.610- 0.755). The calibration curve for probability of recurrence for 7 years and 9 years showed great agreement between prediction by nomogram and actual observation. Furthermore, the AUCs of risk score for 7-year and 9-year were 0.680 and 0.790 respectively. Conclusion This research tried to develop the predictive nomogram of recurrence for patients with endometrioma after cystectomy. The C-index and calibration curve of nomogram, as well as the AUC of the nomogram was potential to predict the recurrence probability. In addition, this predictive nomogram needs external data sets to further validate its prognostic accuracy in the future.
Collapse
Affiliation(s)
- Zhiyue Gu
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Xiaoyan Li
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Jinghua Shi
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Yushi Wu
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Jing Zhang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Chenyu Zhang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Hailan Yan
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| | - Jinhua Leng
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.,National Clinical Research Center for Obstetric and Gynecologic Diseases, Beijing, China
| |
Collapse
|
23
|
Bäumler M, Heiss N, Druckmann R. Endometriosis at all ages: diagnostic ultrasound. Horm Mol Biol Clin Investig 2022; 43:151-157. [PMID: 35654472 DOI: 10.1515/hmbci-2021-0082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Accepted: 03/13/2022] [Indexed: 11/15/2022]
Abstract
Endometriosis is a gynecological disease affecting about 10% of the female population. The multifactorial hormonal, inflammatory, genetic, mental and behavior pathogenesis can result in chronic pelvic pain, blooding disorders and infertility causing disruption of quality of life. Correct diagnosis of the extension and topography is substantial in defining the adequate therapeutic strategy. In an increasing proportion of the cases, endometriosis is being managed medically and para-medically; diagnostic or therapeutic surgery can often be avoided or delayed. Transvaginal sonography is considered being the first-line imaging method in the diagnosis of pelvic endometriosis. The paradigm shift from the belief that endometriosis only affects women of reproductive age has drawn attention to endometriosis in both premenarchal and postmenopausal patients. This review resumes the actually recommended ultrasound signs in the case of patients in menstrual age. Specific diagnostic approaches in adolescent and menopausal patients are highlighted.
Collapse
Affiliation(s)
- Marcel Bäumler
- Department of Gynécologie-Obstétrique, CHU Nimes, Nimes, France
| | - Niko Heiss
- Department of Gynécologie-Obstétrique, CHU Nimes, Nimes, France
| | | |
Collapse
|
24
|
Orlov S, Jokubkiene L. Prevalence of endometriosis and adenomyosis at transvaginal ultrasound examination in symptomatic women. Acta Obstet Gynecol Scand 2022; 101:524-531. [PMID: 35224723 DOI: 10.1111/aogs.14337] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2022] [Revised: 02/07/2022] [Accepted: 02/10/2022] [Indexed: 11/26/2022]
Abstract
INTRODUCTION Prevalence of endometriosis is commonly reported based on surgery findings and varies widely depending on study population and indication for surgery. Symptoms such as dysmenorrhea, pelvic pain, dyspareunia, dysuria, and dyschezia can be associated with endometriosis and adenomyosis. Transvaginal ultrasound examination is proposed to be the first-line diagnostic method, nevertheless there are no published ultrasound-based studies reporting prevalence of endometriosis and adenomyosis in symptomatic women other than those scheduled for surgery. The aim of this study was to determine the prevalence of endometriosis and adenomyosis as assessed by transvaginal ultrasound in women with symptoms suggestive of endometriosis and adenomyosis. MATERIAL AND METHODS This is a retrospective cross-sectional study performed at a tertiary-care center including 373 symptomatic women who were systematically examined with transvaginal ultrasound by an experienced ultrasound examiner. Before ultrasound examination women filled in a questionnaire including self-assessment of the severity of their symptoms (dysmenorrhea, chronic pelvic pain, dyspareunia, dysuria, dyschezia) using a visual analog scale. Abnormal findings in the uterus, ovaries, bowel, urinary bladder, uterosacral ligaments, and rectovaginal septum were noted, and their size and location were described. Prevalence of endometriosis, adenomyosis, endometrioma, and deep endometriosis in different anatomical locations was reported. RESULTS Prevalence of ovarian endometrioma and/or deep endometriosis was 25% and of adenomyosis was 12%. Prevalence of endometrioma was 20% and of deep endometriosis was 9%, for each location being 8% in the bowel, 3% in the uterosacral ligaments, 3% in the rectovaginal septum and 0.5% in the urinary bladder. CONCLUSIONS In symptomatic women examined with transvaginal ultrasound by an experienced ultrasound examiner, ovarian endometrioma and/or deep endometriosis was found in one of four women and adenomyosis in one of nine women. Deep endometriosis was present in one of 11 women. Despite having symptoms, half of the women had no abnormal ultrasound findings.
Collapse
Affiliation(s)
- Sofie Orlov
- Department of Obstetrics and Gynecology, Ystad Hospital, Ystad, Sweden.,Department of Obstetrics and Gynecology, Skåne University Hospital, Lund University, Malmö, Sweden
| | - Ligita Jokubkiene
- Department of Obstetrics and Gynecology, Skåne University Hospital, Lund University, Malmö, Sweden
| |
Collapse
|
25
|
Young H, Bui TL, Cramer SE, O'Connell R, Houshyar R. Ruptured endometrioma in a nonpregnant patient: a case report. J Med Case Rep 2022; 16:161. [PMID: 35459195 PMCID: PMC9034528 DOI: 10.1186/s13256-022-03361-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 03/05/2022] [Indexed: 11/23/2022] Open
Abstract
Background Endometriomas are a type of ovarian cyst composed of degenerated blood products from hemorrhage of ectopic endometrial tissue. Endometriomas can rupture, causing hemoperitoneum, and present with signs and symptoms similar to other, more common abdominal emergencies. Therefore, they are not often diagnosed preoperatively. Ultrasound and cross-sectional imaging can assist in diagnosis of endometriomas. We present a case of ruptured endometrioma causing massive hemoperitoneum that was initially suspected to represent malignancy with carcinomatosis. Case presentation A 32-year-old Hispanic woman presented with sharp abdominal pain and 15-pound unintentional weight loss over 6 months. Laboratory work was significant for a negative pregnancy test and elevated cancer antigen-125. Computed tomography of the abdomen and pelvis demonstrated a 13-cm complex cystic mass in the left adnexa with moderate hyperdense ascites and omental nodularity. Ultrasound demonstrated a large left adnexal complex cystic structure with internal echoes, and chest computed tomography showed no signs of intrathoracic neoplastic or infectious processes. Her presentation was concerning for malignancy with carcinomatosis. Fluid from a paracentesis was sent for culture and cytology. Diagnostic laparoscopy revealed that the left ovary had been completely replaced by an endometrioma, which had a small ruptured area superiorly. Brown deposits of endometriosis were present on the cyst, omentum, and various peritoneal linings. Tissue samples of the endometrium, myometrium, cervix, ovaries, fallopian tubes, peritoneum, omentum, and paracolic spaces were taken and showed no hyperplastic, dysplastic, or malignant cells on pathology. Conclusions Ruptured endometrioma and ruptured hemorrhagic cyst should be included in the differential diagnosis when a premenopausal female presents with hemoperitoneum in combination with complex adnexal cystic masses in the absence of trauma. Cancer antigen-125 and cancer antigen 19-9 can be falsely elevated in the setting of ruptured endometrioma.
Collapse
Affiliation(s)
- Hayley Young
- Department of Radiological Sciences, University of California Irvine, 101 The City Dr S Building 55, Box 140, Orange, CA, 92868, USA
| | - Thanh-Lan Bui
- Department of Radiological Sciences, University of California Irvine, 101 The City Dr S Building 55, Box 140, Orange, CA, 92868, USA
| | - Scott E Cramer
- Department of Radiological Sciences, University of California Irvine, 101 The City Dr S Building 55, Box 140, Orange, CA, 92868, USA
| | - Ryan O'Connell
- Department of Pathology, University of California Irvine, 101 The City Dr S Building 1, Rm 3003, Orange, CA, 92868, USA
| | - Roozbeh Houshyar
- Department of Radiological Sciences, University of California Irvine, 101 The City Dr S Building 55, Box 140, Orange, CA, 92868, USA.
| |
Collapse
|
26
|
Thammasiri C, Amnatbuddee S, Sothornwit J, Temtanakitpaisan T, Buppasiri P. A Cross-Sectional Study on the Quality of Life in Women with Endometrioma. Int J Womens Health 2022; 14:9-14. [PMID: 35046731 PMCID: PMC8760997 DOI: 10.2147/ijwh.s341603] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 12/28/2021] [Indexed: 11/23/2022] Open
Abstract
PURPOSE To evaluate the quality of life (QoL) of women with endometrioma and explore the associated factors. PATIENTS AND METHODS A cross-sectional study was conducted between August 2020 and March 2021. A total of 99 women diagnosed with ovarian endometrioma with at least one endometriosis-associated symptom completed the Endometriosis Health Profile 30 (EHP-30) questionnaire for their QoL score before treatment for ovarian endometrioma. The questionnaire comprises a central questionnaire (30 items) and a modular questionnaire (23 items divided into 6 sections). Demographics and QoL scores were analyzed using descriptive statistics and multivariable linear regression or median regression. RESULTS The mean QoL score was 35.0±15.8 (range, 16.0±21.2 in the social support dimension to 45.1±24.4 in the control and powerlessness dimension). In the modular questionnaire, the highest score was in the infertility domain, while the lowest was in the relationship with the physician domain. The pain score and chronic pelvic pain (CPP) were independent correlation factors for a higher total EHP-30 score: the higher the total EHP-30, the poorer the QoL. CPP was positively correlated with the QoL score in the work domain. CONCLUSION The present study revealed that CPP was the factor associated with a worse QoL and work performance in women with endometrioma based on a disease-specific, EHP-30 questionnaire.
Collapse
Affiliation(s)
- Chutikarn Thammasiri
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Siriruthai Amnatbuddee
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Jen Sothornwit
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Teerayut Temtanakitpaisan
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Pranom Buppasiri
- Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| |
Collapse
|
27
|
Bean E, Naftalin J, Horne A, Saridogan E, Cutner A, Jurkovic D. Prevalence of deep and ovarian endometriosis in early pregnancy: ultrasound diagnostic study. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2022; 59:107-113. [PMID: 34435713 DOI: 10.1002/uog.24756] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/10/2021] [Revised: 07/12/2021] [Accepted: 08/17/2021] [Indexed: 06/13/2023]
Abstract
OBJECTIVE To assess the prevalence and morphological appearance of deep endometriosis and ovarian endometrioma using pelvic ultrasound examination in women attending for an early pregnancy assessment. METHODS This was a prospective observational study set within a dedicated early pregnancy unit. The study included 1341 consecutive women who attended for an early pregnancy assessment for reassurance or because of suspected early pregnancy complications. All women underwent a transvaginal scan to assess the location and viability of their pregnancy. In addition, a detailed examination of pelvic organs was carried out to detect the presence of endometriosis and other gynecological abnormalities. Data analysis was performed using logistic regression and multivariable analysis. RESULTS The prevalence of deep endometriosis and/or ovarian endometrioma in women attending our early pregnancy unit was 4.9% (95% CI, 3.8-6.2%). In 33/66 (50.0% (95% CI, 37.9-62.1%)) women with endometriosis, this was a new diagnosis that was made during their early pregnancy scan. On multivariable analysis, the presence of endometriosis was strongly associated with a history of subfertility (odds ratio (OR), 3.15 (95% CI, 1.63-6.07)) and presence of a congenital uterine anomaly (OR, 5.69 (95% CI, 2.17-14.9)) and uterine fibroids (OR, 2.37 (95% CI, 1.31-4.28)). Morphological changes typical of decidualization were seen in 11/33 (33.3% (95% CI, 17.2-49.4%)) women with ovarian endometrioma and 18/57 (31.6% (95% CI, 19.5-43.7%)) women with deep endometriotic nodules. CONCLUSIONS Deep endometriosis and ovarian endometrioma were present in a significant proportion of women attending for early pregnancy assessment. The prevalence varied depending on a history of subfertility, and therefore is likely to differ significantly among populations, depending on their characteristics. Ultrasound is a useful tool for the detection of endometriosis in early pregnancy and the identification of women who may benefit from specialist antenatal care. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.
Collapse
Affiliation(s)
- E Bean
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - J Naftalin
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - A Horne
- MRC Centre for Reproductive Health, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK
| | - E Saridogan
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - A Cutner
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - D Jurkovic
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| |
Collapse
|
28
|
Younis JS. Is Oocyte Quality Impaired in Cases With Ovarian Endometriosis? A Second Look Into the Clinical Setting. Front Endocrinol (Lausanne) 2022; 13:921032. [PMID: 35846314 PMCID: PMC9279608 DOI: 10.3389/fendo.2022.921032] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/15/2022] [Accepted: 06/06/2022] [Indexed: 11/24/2022] Open
Affiliation(s)
- Johnny S. Younis
- Reproductive Medicine, Department of Obstetrics and Gynecology, Baruch-Padeh Medical Center, Poriya, Israel
- Azrieili Faculty of Medicine in Galilee, Safed, Bar-Ilan University, Safed, Israel
- *Correspondence: Johnny S. Younis,
| |
Collapse
|
29
|
El-Maadawy SM, Alaaeldin N, Nagy CB. Role of preoperative ultrasound mapping in the surgical management of deep infiltrating endometriosis: a prospective observational study. THE EGYPTIAN JOURNAL OF RADIOLOGY AND NUCLEAR MEDICINE 2021. [DOI: 10.1186/s43055-021-00526-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
Endometriosis is a challenging gynecological condition that has a profound influence on the quality of life of affected women. Transvaginal ultrasound is considered the first-line imaging method in preoperative assessment of the extent and severity of endometriosis. Accurate preoperative mapping can aid the surgeon in patient counselling, selection of the most appropriate surgical method that minimizes the operative and post-operative complications. The aim of our study is to evaluate the accuracy of transvaginal sonography (TVS) in precisely assessing the size, location and extent of deep infiltrating endometriosis (DIE) using a new modified endometriosis mapping proforma with histopathological confirmation. Our prospective observational study included 101 women with clinically suspected DIE who underwent TVS followed by laparoscopy from October 2018 to December 2020 with a maximum of 4 weeks interval. Precise mapping of DIE was done during TVS and laparoscopy. Results were correlated with histopathology findings.
Results
DIE was confirmed by histopathology in 88 patients. Sensitivity and specificity for individual DIE locations were rectovaginal septum 67.9% and 98.6%; vagina 52.2% and 98.7%; uterosacral ligaments 82.5% and 96.2%; torus 96.4% and 97.3%; parametrium 68.8% and 96.9%; rectum 100% and 98.8%; bladder 100% and 100%, ureters 63.4% and 99.0%; scar endometriosis 100% and 100%; pouch of Douglas obliteration 97.7% and 100%. No statistically significant difference was detected between ultrasound and histopathology size. Ultrasound tended to underestimate the lesion size; the underestimation was more pronounced for lesions > 3 cm. “Butterfly” and “tram-track” signs are two new sonographic signs related to posterior compartment DIE. No post-operative complications were recorded. There were no cases of DIE recurrence. Eleven out of 22 cases of infertility achieved pregnancy during 18 months follow-up.
Conclusion
TVS provides a thorough and accurate evaluation of the extent of endometriosis. An experienced radiologist can use E-PEP to provide an accurate demonstration of the location and extent of DIE which helps the surgeon select the most appropriate surgical approach ensuring radical treatment of the disease and minimizing short- and long-term complications.
Collapse
|
30
|
Horan M, Glover L, Wingfield M. Managing endometrioma to optimize future fertility. Int J Gynaecol Obstet 2021; 158:512-519. [PMID: 34767627 DOI: 10.1002/ijgo.14020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 11/01/2021] [Accepted: 11/10/2021] [Indexed: 11/11/2022]
Abstract
The management of endometriomas in women wishing to preserve their fertility is complex. While surgery can help to achieve pregnancy in some, it may also have a detrimental effect on a woman's ovarian reserve. The present article reviews the impact of endometriomas on fertility and the different management approaches that should be considered in women who wish to preserve their fertility. This study also reviews the role of assisted reproduction in the setting of endometriomas, and the evolving role of oocyte cryopreservation for this benign but progressive disease. Using evidence from the latest guidelines and major publications, we emphasize the need to consider the woman's future fertility when navigating the diverse range of management strategies available, and outline an evidence-based framework to help facilitate fertility-friendly discussion, counseling and management of this complex disease.
Collapse
Affiliation(s)
- Maebh Horan
- Merrion Fertility Clinic, Dublin 2, Ireland.,Department of Obstetrics and Gynecology, National Maternity Hospital, Dublin 2, Ireland.,School of Medicine, University College Dublin, Dublin 4, Ireland
| | - Louise Glover
- Merrion Fertility Clinic, Dublin 2, Ireland.,School of Medicine, University College Dublin, Dublin 4, Ireland
| | - Mary Wingfield
- Merrion Fertility Clinic, Dublin 2, Ireland.,Department of Obstetrics and Gynecology, National Maternity Hospital, Dublin 2, Ireland.,School of Medicine, University College Dublin, Dublin 4, Ireland
| |
Collapse
|
31
|
External Validation of the IOTA Classification in Women with Ovarian Masses Suspected to Be Endometrioma. J Clin Med 2021; 10:jcm10132971. [PMID: 34279456 PMCID: PMC8269298 DOI: 10.3390/jcm10132971] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2021] [Revised: 06/24/2021] [Accepted: 06/27/2021] [Indexed: 01/04/2023] Open
Abstract
The study aimed to perform external validation of the International Ovarian Tumor Analysis (IOTA) classification of adnexal masses as benign or malignant in women with suspected endometrioma. A retrospective study including women referred to an endometriosis tertiary referral center for dedicated transvaginal ultrasound (TVUS). Adnexal masses were evaluated using the IOTA classification simple descriptors, simple rules and expert opinion. The reference standard was definitive histology after mass removal at laparoscopy. In total, 621 women were evaluated and divided into four groups: endometrioma on TVUS and confirmed on surgery (Group 1 = 181), endometrioma on TVUS but other benign cysts on surgery (Group 2 = 9), other cysts on TVUS but endometrioma on surgery (Group 3 = 2), masses classified as other findings or suspicious for malignancy on TVUS and confirmed on surgery (Group 4 = 5 potentially malignant, 11 benign). This gave a sensitivity 98.9%, specificity 64%, positive 95.3% and negative 88.9% predictive values, positive 2.74 and negative 0.02 likelihood ratios and 94.7% overall accuracy. The surgical diagnosis for the five masses suspected to be malignant was: borderline serous tumor (2), borderline mucinous tumor (2), and endometrioid lesion with complex hyperplasia without atypia (1). The conclusions were that the IOTA classification simple descriptors, simple rules and expert opinion performs well for classifying adnexal masses suspected to be endometrioma. The most common potentially malignant masses in these women were borderline ovarian tumors.
Collapse
|
32
|
Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa AC, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2021; 58:148-168. [PMID: 33794043 DOI: 10.1002/uog.23635] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumors, including imaging techniques, biomarkers and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the preoperative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the preoperative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.
Collapse
Affiliation(s)
- D Timmerman
- Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium
| | - F Planchamp
- Clinical Research Unit, Institut Bergonie, Bordeaux, France
| | - T Bourne
- Department of Development and Regeneration, KU Leuven, Leuven, Belgium
- Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium
- Department of Metabolism, Digestion and Reproduction, Queen Charlotte's & Chelsea Hospital, Imperial College, London, UK
| | - C Landolfo
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - A du Bois
- Department of Gynaecology and Gynaecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany
| | - L Chiva
- Department of Gynaecology and Obstetrics, University Clinic of Navarra, Madrid, Spain
| | - D Cibula
- Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic
| | - N Concin
- Department of Gynaecology and Gynaecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany
- Department of Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - D Fischerova
- Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University, General University Hospital in Prague, Prague, Czech Republic
| | - W Froyman
- Department of Obstetrics and Gynecology, University Hospitals KU Leuven, Leuven, Belgium
| | - G Gallardo
- Department of Radiology, University Clinic of Navarra, Madrid, Spain
| | - B Lemley
- Patient Representative, President of Kraefti Underlivet (KIU), Denmark
- Chair Clinical Trial Project of the European Network of Gynaecological Cancer Advocacy Groups, ENGAGe
| | - A Loft
- Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - L Mereu
- Department of Gynecology and Obstetrics, Gynecologic Oncology Unit, Santa Chiara Hospital, Trento, Italy
| | - P Morice
- Department of Gynaecological Surgery, Institut Gustave Roussy, Villejuif, France
| | - D Querleu
- Division of Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
- Department of Obstetrics and Gynecologic Oncology, University Hospital, Strasbourg, France
| | - A C Testa
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - I Vergote
- Department of Obstetrics and Gynaecology and Gynaecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium
| | - V Vandecaveye
- Department of Radiology, University Hospitals Leuven, Leuven, Belgium
- Division of Translational MRI, Department of Imaging & Pathology KU Leuven, Leuven, Belgium
| | - G Scambia
- Department of Woman, Child and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- Institute of Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - C Fotopoulou
- Department of Gynecologic Oncology, Hammersmith Hospital, Imperial College, London, UK
| |
Collapse
|
33
|
Ștefan RA, Ștefan PA, Mihu CM, Csutak C, Melincovici CS, Crivii CB, Maluțan AM, Hîțu L, Lebovici A. Ultrasonography in the Differentiation of Endometriomas from Hemorrhagic Ovarian Cysts: The Role of Texture Analysis. J Pers Med 2021; 11:jpm11070611. [PMID: 34203314 PMCID: PMC8306221 DOI: 10.3390/jpm11070611] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 06/21/2021] [Accepted: 06/25/2021] [Indexed: 01/08/2023] Open
Abstract
The ultrasonographic (US) features of endometriomas and hemorrhagic ovarian cysts (HOCs) are often overlapping. With the emergence of new computer-aided diagnosis techniques, this is the first study to investigate whether texture analysis (TA) could improve the discrimination between the two lesions in comparison with classic US evaluation. Fifty-six ovarian cysts (endometriomas, 30; HOCs, 26) were retrospectively included. Four classic US features of endometriomas (low-level internal echoes, perceptible walls, no solid components, and less than five locules) and 275 texture parameters were assessed for every lesion, and the ability to identify endometriomas was evaluated through univariate, multivariate, and receiver operating characteristics analyses. The sensitivity (Se) and specificity (Sp) were calculated with 95% confidence intervals (CIs). The texture model, consisting of seven independent predictors (five variations of difference of variance, image contrast, and the 10th percentile; 100% Se and 100% Sp), was able to outperform the ultrasound model composed of three independent features (low-level internal echoes, perceptible walls, and less than five locules; 74.19% Se and 84.62% Sp) in the diagnosis of endometriomas. The TA showed statistically significant differences between the groups and high diagnostic value, but it remains unclear if the textures reflect the intrinsic histological characteristics of the two lesions.
Collapse
Affiliation(s)
- Roxana-Adelina Ștefan
- Histology, Morphological Sciences Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Louis Pasteur Street, Number 4, 400349 Cluj-Napoca, Romania; (R.-A.Ș.); (C.M.M.); (C.S.M.)
- Obstetrics and Gynecology Clinic “Dominic Stanca”, County Emergency Hospital, 21 Decembrie 1989 Boulevard, Number 55, 400094 Cluj-Napoca, Romania;
| | - Paul-Andrei Ștefan
- Anatomy and Embryology, Morphological Sciences Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Victor Babes, Street, Number 8, 400012 Cluj-Napoca, Romania;
- Radiology and Imaging Department, County Emergency Hospital, Cluj-Napoca, Clinicilor Street, Number 5, 400006 Cluj-Napoca, Romania; (C.C.); (A.L.)
- Correspondence: or
| | - Carmen Mihaela Mihu
- Histology, Morphological Sciences Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Louis Pasteur Street, Number 4, 400349 Cluj-Napoca, Romania; (R.-A.Ș.); (C.M.M.); (C.S.M.)
- Radiology and Imaging Department, County Emergency Hospital, Cluj-Napoca, Clinicilor Street, Number 5, 400006 Cluj-Napoca, Romania; (C.C.); (A.L.)
| | - Csaba Csutak
- Radiology and Imaging Department, County Emergency Hospital, Cluj-Napoca, Clinicilor Street, Number 5, 400006 Cluj-Napoca, Romania; (C.C.); (A.L.)
- Radiology, Surgical Specialties Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Clinicilor Street, Number 3-5, 400006 Cluj-Napoca, Romania
| | - Carmen Stanca Melincovici
- Histology, Morphological Sciences Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Louis Pasteur Street, Number 4, 400349 Cluj-Napoca, Romania; (R.-A.Ș.); (C.M.M.); (C.S.M.)
- Radiology and Imaging Department, County Emergency Hospital, Cluj-Napoca, Clinicilor Street, Number 5, 400006 Cluj-Napoca, Romania; (C.C.); (A.L.)
| | - Carmen Bianca Crivii
- Anatomy and Embryology, Morphological Sciences Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Victor Babes, Street, Number 8, 400012 Cluj-Napoca, Romania;
| | - Andrei Mihai Maluțan
- Obstetrics and Gynecology Clinic “Dominic Stanca”, County Emergency Hospital, 21 Decembrie 1989 Boulevard, Number 55, 400094 Cluj-Napoca, Romania;
- Obstetrics and Gynecology Clinic II, Mother and Child Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, 21 Decembrie 1989 Boulevard, Number 55, 400094 Cluj-Napoca, Romania
| | - Liviu Hîțu
- Doctoral School, Iuliu Hațieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania;
| | - Andrei Lebovici
- Radiology and Imaging Department, County Emergency Hospital, Cluj-Napoca, Clinicilor Street, Number 5, 400006 Cluj-Napoca, Romania; (C.C.); (A.L.)
- Radiology, Surgical Specialties Department, “Iuliu Hațieganu” University of Medicine and Pharmacy, Clinicilor Street, Number 3-5, 400006 Cluj-Napoca, Romania
| |
Collapse
|
34
|
Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo Madueño G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa AC, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. Int J Gynecol Cancer 2021; 31:961-982. [PMID: 34112736 PMCID: PMC8273689 DOI: 10.1136/ijgc-2021-002565] [Citation(s) in RCA: 56] [Impact Index Per Article: 18.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2021] [Accepted: 03/08/2021] [Indexed: 02/06/2023] Open
Abstract
The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group, and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the pre-operative diagnosis of ovarian tumors, including imaging techniques, biomarkers, and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the pre-operative diagnosis of ovarian tumors and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when a consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the pre-operative diagnosis of ovarian tumors and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.
Collapse
Affiliation(s)
- Dirk Timmerman
- Gynecology and Obstetrics, University Hospitals KU Leuven, Leuven, Belgium .,Development and Regeneration, KU Leuven, Leuven, Belgium
| | | | - Tom Bourne
- Gynecology and Obstetrics, University Hospitals KU Leuven, Leuven, Belgium.,Development and Regeneration, KU Leuven, Leuven, Belgium.,Metabolism Digestion and Reproduction, Queen Charlotte's & Chelsea Hospital, Imperial College, London, UK
| | - Chiara Landolfo
- Woman, Child and Public Health, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
| | - Andreas du Bois
- Gynaecology and Gynaecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany
| | - Luis Chiva
- Gynaecology and Obstetrics, University Clinic of Navarra, Madrid, Spain
| | - David Cibula
- Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Nicole Concin
- Gynaecology and Gynaecological Oncology, Evangelische Kliniken Essen-Mitte, Essen, Germany.,Obstetrics and Gynecology, Medical University of Innsbruck, Innsbruck, Austria
| | - Daniela Fischerova
- Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
| | - Wouter Froyman
- Gynecology and Obstetrics, University Hospitals KU Leuven, Leuven, Belgium
| | | | - Birthe Lemley
- European Network of Gynaecological Cancers Advocacy Groups (ENGAGe) Executive Group, Prague, Czech Republic.,KIU - Patient Organisation for Women with Gynaecological Cancer, Copenhagen, Denmark
| | - Annika Loft
- Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
| | - Liliana Mereu
- Gynecology and Obstetrics, Gynecologic Oncology Unit, Santa Chiara Hospital, Trento, Italy
| | - Philippe Morice
- Gynaecological Surgery, Institut Gustave Roussy, Villejuif, France
| | - Denis Querleu
- Gynecologic Oncology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.,Obstetrics and Gynecologic Oncology, University Hospital, Strasbourg, France
| | - Antonia Carla Testa
- Woman, Child and Public Health, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.,Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - Ignace Vergote
- Obstetrics and Gynaecology and Gynaecologic Oncology, University Hospital Leuven, Leuven Cancer Institute, Leuven, Belgium
| | - Vincent Vandecaveye
- Radiology, University Hospitals Leuven, Leuven, Belgium.,Division of Translational MRI, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Giovanni Scambia
- Woman, Child and Public Health, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.,Obstetrics and Gynecology, Università Cattolica del Sacro Cuore, Rome, Italy
| | | |
Collapse
|
35
|
Timmerman D, Planchamp F, Bourne T, Landolfo C, du Bois A, Chiva L, Cibula D, Concin N, Fischerova D, Froyman W, Gallardo G, Lemley B, Loft A, Mereu L, Morice P, Querleu D, Testa C, Vergote I, Vandecaveye V, Scambia G, Fotopoulou C. ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumours. Facts Views Vis Obgyn 2021; 13:107-130. [PMID: 34107646 PMCID: PMC8291986 DOI: 10.52054/fvvo.13.2.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumours, including imaging techniques, biomarkers and prediction models. ESGO/ISUOG/IOTA/ESGE nominated a multidisciplinary international group, including expert practising clinicians and researchers who have demonstrated leadership and expertise in the preoperative diagnosis of ovarian tumours and management of patients with ovarian cancer (19 experts across Europe). A patient representative was also included in the group. To ensure that the statements were evidence-based, the current literature was reviewed and critically appraised. Preliminary statements were drafted based on the review of the relevant literature. During a conference call, the whole group discussed each preliminary statement and a first round of voting was carried out. Statements were removed when a consensus among group members was not obtained. The voters had the opportunity to provide comments/suggestions with their votes. The statements were then revised accordingly. Another round of voting was carried out according to the same rules to allow the whole group to evaluate the revised version of the statements. The group achieved consensus on 18 statements. This Consensus Statement presents these ESGO/ISUOG/IOTA/ESGE statements on the preoperative diagnosis of ovarian tumours and the assessment of carcinomatosis, together with a summary of the evidence supporting each statement.
Collapse
|
36
|
Martire FG, Zupi E, Lazzeri L, Morosetti G, Conway F, Centini G, Solima E, Pietropolli A, Piccione E, Exacoustos C. Transvaginal Ultrasound Findings After Laparoscopic Rectosigmoid Segmental Resection for Deep Infiltrating Endometriosis. JOURNAL OF ULTRASOUND IN MEDICINE : OFFICIAL JOURNAL OF THE AMERICAN INSTITUTE OF ULTRASOUND IN MEDICINE 2021; 40:1219-1228. [PMID: 32936475 DOI: 10.1002/jum.15505] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2020] [Revised: 08/14/2020] [Accepted: 08/22/2020] [Indexed: 06/11/2023]
Abstract
OBJECTIVES To evaluate transvaginal ultrasound (TVUS) findings in patients who underwent segmental rectosigmoid resection for deep infiltrating endometriosis (DIE) and to correlate postsurgical ultrasound findings with symptoms. METHODS A retrospective study including 50 premenopausal women with bowel endometriosis who underwent segmental rectosigmoid resection was conducted. Within 12 months after surgery, a TVUS examination was conducted in all patients to evaluate the presence of postsurgical endometriosis locations and symptoms, including dysmenorrhea, dyspareunia, dysuria, dyschezia, and chronic pelvic pain. Pelvic pain was assessed in all women by a visual analog scale. RESULTS At the follow-up 32 of 50 patients were receiving medical treatment, whereas 18 women declined postsurgical medical therapy and tried to conceive. A high percentage of adhesions (90%) was found. A negative sliding sign (a simple diagnostic sign that can be performed during a TVUS examination, consisting of gentle pressure applied by both the vaginal transducer and the examiner's hand on the abdomen; if the uterus does not glide freely along with the rectum and posterior fornix, the sign is considered negative, and adhesions can be suspected) was found in 29 (58%) women and was associated with bowel symptoms. Recurrence of posterior DIE was found in 9 cases (18%) and endometriomas in 8 cases (16%). Adenomyosis was observed in 80% of women and was present in all symptomatic patients. CONCLUSIONS After rectosigmoid segmental resection patients with DIE may continue to be symptomatic, and postoperative TVUS may reveal foci of disease or pelvic adhesions. Moreover, adenomyosis could be linked to symptoms experienced during follow up. Women should be aware that painful symptoms and alterations of pelvic organs could still be present after surgery and be detectable by TVUS.
Collapse
Affiliation(s)
- Francesco G Martire
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| | - Errico Zupi
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
| | - Lucia Lazzeri
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
| | - Giulia Morosetti
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| | - Francesca Conway
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| | - Gabriele Centini
- Department of Molecular and Developmental Medicine, University of Siena, Siena, Italy
| | - Eugenio Solima
- Azienda Socio Sanitaria Territoriale Fatebenefratelli, Hospital Sacco, Milan, Italy
| | - Adalgisa Pietropolli
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| | - Emilio Piccione
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| | - Caterina Exacoustos
- Department of Surgical Sciences, Gynecologic Unit, University of Rome Tor Vergata, Rome, Italy
| |
Collapse
|
37
|
Del Forno S, Cofano M, Degli Esposti E, Manzara F, Lenzi J, Raimondo D, Arena A, Paradisi R, Casadio P, Seracchioli R. Long-Term Medical Therapy after Laparoscopic Excision of Ovarian Endometriomas: Can We Reduce and Predict the Risk of Recurrence? Gynecol Obstet Invest 2021; 86:170-176. [PMID: 33849018 DOI: 10.1159/000514310] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2020] [Accepted: 01/04/2021] [Indexed: 11/19/2022]
Abstract
OBJECTIVES Up to 32% of women experience anatomic recurrence after conservative surgery for endometriomas, while pain recurs in 10-40% of cases. Long-term postoperative hormonal therapy is recommended to prevent disease recurrence. We evaluated the efficacy of long-term therapy with estroprogestins (EPs) or progestins (Ps) in preventing endometrioma recurrence, as identifiable cysts and subjective symptoms, after laparoscopic excision. DESIGN This retrospective cohort study included 375 women submitted to laparoscopic endometrioma excision. Women were followed up at 6 and 12 months and then yearly after surgery. Based on postoperative medical therapy, women were divided into 4 groups: nonusers, cyclic EP users, continuous EP users, and progestogen users. Materials, Setting, Methods: Anamnestic and anthropometric characteristics were collected as well as clinical and surgical data. Gynecological examination, and transvaginal and transabdominal ultrasound scans were performed. Pain (numerical rating score >5) and endometrioma recurrence at ultrasound (ovarian cyst with typical sonographic features ≥10 mm in mean diameter) were recorded at each examination. The reoperation rate in women with recurrence was investigated. RESULTS The median follow-up was 3.7 years with a maximum of 16.7 years. Most patients used EPs (119 cyclic and 61 continuous users), 95 used P, and 100 were nonusers. In 135 women (36%), endometriotic cyst recurrence was diagnosed, with a mean diameter of 18.7 ± 10.8 mm (range 10-55 mm). The median recurrent cyst-free time was 7.9 years (95% CI 5.8-10.8). Dysmenorrhea was the first symptom to reappear, affecting 162 patients (43.2%). Upon multivariable regression analysis, continuous users had a lower risk of relapse (OR 0.56, 95% CI 0.32-0.99), in terms of both cysts and symptom recurrence, than patients who received no medications. The reoperation rate was 16.2%. LIMITATIONS The main limitation of this study is its retrospective design. Also, women switching therapies throughout the follow-up period were sorted into one of the study groups based on the longest treatment taken, without considering the discontinuation rates. CONCLUSIONS Long-term EPs, administered in a continuous regimen and starting immediately after conservative surgery for endometriomas, seem to reduce the disease recurrence risk.
Collapse
Affiliation(s)
- Simona Del Forno
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Maria Cofano
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Eugenia Degli Esposti
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Federica Manzara
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Jacopo Lenzi
- Dipartimento di Scienze Biomediche e Neuromotorie (DIBINEM), Alma Mater Studiorum - University of Bologna, Bologna, Italy
| | - Diego Raimondo
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Alessandro Arena
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Roberto Paradisi
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Paolo Casadio
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - Renato Seracchioli
- Gynecology and Human Reproduction Physiopathology, Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| |
Collapse
|
38
|
Wattanayingcharoenchai R, Rattanasiri S, Charakorn C, Attia J, Thakkinstian A. Postoperative hormonal treatment for prevention of endometrioma recurrence after ovarian cystectomy: a systematic review and network meta-analysis. BJOG 2021; 128:25-35. [PMID: 32558987 PMCID: PMC7754428 DOI: 10.1111/1471-0528.16366] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/05/2020] [Indexed: 01/17/2023]
Abstract
BACKGROUND The efficacy of hormonal regimens for the prevention of endometrioma recurrence in women who have undergone conservative surgery is still controversial. OBJECTIVE To compare the efficacy of different hormonal regimens in this context and to rank them. SEARCH STRATEGY MEDLINE and Scopus databases were searched through January 2020. SELECTION CRITERIA Randomised controlled trials (RCTs) or cohorts, comparing the effect of any pair of interventions (i.e. cyclic oral contraceptives [OC], continuous OC, gonadotropin-releasing hormone agonist [GnRHa], dienogest [DNG], levonorgestrel-releasing intrauterine system [LNG-IUS] and expectant management) on endometrioma recurrence were selected. DATA COLLECTION AND ANALYSIS Data were independently extracted by two reviewers. Relative treatment effects were estimated using network meta-analysis (NMA) and ranked in descending order. MAIN RESULTS Six RCTs (675 patients) and 16 cohorts (3089 patients) were included. NMA of the RCTs involving expectant management, cyclic OC, continuous OC, GnRHa and GnRHa + LNG-IUS, showed that all hormonal regimens had a nonsignificant lower risk of endometrioma recurrence compared with expectant management. NMA of the cohorts involving expectant, cyclic OC, continuous OC, GnRHa, DNG, LNG-IUS, GnRHa + OC, and GnRHa + LNG-IUS indicated that LNG-IUS, DNG, continuous OC, GnRHa + OC and cyclic OC had a significantly lower risk of endometrioma recurrence than expectant management. LNG-IUS was ranked highest, followed by DNG and GnRHa + LNG-IUS. Long-term use of hormonal treatment either OC or progestin had a significantly lower risk of endometrioma recurrence than expectant treatment. CONCLUSION In the NMA of RCTs, there was no evidence supporting hormonal treatment for postoperative prevention of endometrioma recurrence. This was at odds with the cohort evidence, which found the protective effect of OC and progestin regimens, especially long-term treatment. Large-scale RCTs of these agents are still required. TWEETABLE ABSTRACT Hormonal regimens given as long-term treatment tend to reduce risk of endometrioma recurrence after conservative surgery.
Collapse
Affiliation(s)
- R Wattanayingcharoenchai
- Department of Clinical Epidemiology and BiostatisticsFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand,Department of Obstetrics and GynaecologyFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
| | - S Rattanasiri
- Department of Clinical Epidemiology and BiostatisticsFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
| | - C Charakorn
- Department of Clinical Epidemiology and BiostatisticsFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand,Department of Obstetrics and GynaecologyFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
| | - J Attia
- Centre for Clinical Epidemiology and BiostatisticsSchool of Medicine and Public HealthFaculty of Health and MedicineUniversity of NewcastleNew LambtonAustralia
| | - A Thakkinstian
- Department of Clinical Epidemiology and BiostatisticsFaculty of Medicine Ramathibodi HospitalMahidol UniversityBangkokThailand
| |
Collapse
|
39
|
Guo Z, Feng P, Chen X, Tang R, Yu Q. Developing Preoperative Nomograms to Predict Any-Stage and Stage III-IV Endometriosis in Infertile Women. Front Med (Lausanne) 2020; 7:570483. [PMID: 33195317 PMCID: PMC7642458 DOI: 10.3389/fmed.2020.570483] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2020] [Accepted: 09/21/2020] [Indexed: 11/19/2022] Open
Abstract
Study objective: To generate and validate nomograms to predict any-stage and stage III-IV endometriosis before surgery in infertile women. Design: A single center retrospective cohort study. Setting: University affiliated hospital. Patients: Infertile patients (n = 1,016) who underwent reproductive surgery between July 1, 2016 and June 30, 2019. Interventions: None. Main outcome measurements: We randomly selected 2/3 of the included patients (667 patients, training sample) to analyze and generate predictive models and validated the models on the remaining patients (339 patients, validation sample). A multivariate logistic regression model was used with the training sample to select variables using a back stepwise procedure. Nomograms to predict any-stage and stage III–IV endometriosis were constructed separately. The discriminations and calibrations of both nomograms were tested on the overall population and a subgroup without endometrioma diagnosed on transvaginal sonography (TVS) of training and validation samples. The impact of different variables in these models was evaluated. Results: There were 377 (55.7%) women in the training sample and 196 (57.8%) in the validation sample who were diagnosed with endometriosis. The nomogram predicting any-stage endometriosis had an area under the curve (AUC) of 0.760 for the training sample and 0.744 for the validation sample, with favorable calibrations in the overall population. However, the performance was significantly decreased in patients without endometrioma on TVS, with an AUC of 0.726 in the training sample and 0.694 in the validation sample. Similarly, the nomogram predicting stage III–IV endometriosis had an AUC of 0.833 and 0.793 for the training and validation samples, respectively, as well as a favorable calibration. However, the performance of the nomogram on patients without endometrioma on TVS was poor. Endometrioma on TVS strongly predicted both any stage and stage III–IV endometriosis on both samples. Conclusion: We developed nomograms to predict any-stage and stage III–IV endometriosis but their performance were significantly decreased in patients without endometrioma on TVS. Endometrioma on TVS strongly predicted any and III–IV stage endometriosis in both sample groups. Therefore, we recommend that this study be used as encouragement to advance the utilization of advanced imaging for endometriosis for better clinical prognosis.
Collapse
Affiliation(s)
- Zaixin Guo
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| | - Penghui Feng
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| | - Xiaohan Chen
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| | - Ruiyi Tang
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| | - Qi Yu
- Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
| |
Collapse
|
40
|
Scioscia M, Virgilio BA, Laganà AS, Bernardini T, Fattizzi N, Neri M, Guerriero S. Differential Diagnosis of Endometriosis by Ultrasound: A Rising Challenge. Diagnostics (Basel) 2020; 10:E848. [PMID: 33092074 PMCID: PMC7589178 DOI: 10.3390/diagnostics10100848] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2020] [Accepted: 10/15/2020] [Indexed: 12/22/2022] Open
Abstract
Ultrasound is an effective tool to detect and characterize endometriosis lesions. Variances in endometriosis lesions' appearance and distorted anatomy secondary to adhesions and fibrosis present as major difficulties during the complete sonographic evaluation of pelvic endometriosis. Currently, differential diagnosis of endometriosis to distinguish it from other diseases represents the hardest challenge and affects subsequent treatment. Several gynecological and non-gynecological conditions can mimic deep-infiltrating endometriosis. For example, abdominopelvic endometriosis may present as atypical lesions by ultrasound. Here, we present an overview of benign and malignant diseases that may resemble endometriosis of the internal genitalia, bowels, bladder, ureter, peritoneum, retroperitoneum, as well as less common locations. An accurate diagnosis of endometriosis has significant clinical impact and is important for appropriate treatment.
Collapse
Affiliation(s)
- Marco Scioscia
- Department of Obstetrics and Gynecology, Policlinico Hospital, 35031 Abano Terme, PD, Italy; (M.S.); (B.A.V.); (T.B.); (N.F.)
| | - Bruna A. Virgilio
- Department of Obstetrics and Gynecology, Policlinico Hospital, 35031 Abano Terme, PD, Italy; (M.S.); (B.A.V.); (T.B.); (N.F.)
| | - Antonio Simone Laganà
- Department of Obstetrics and Gynecology, “Filippo Del Ponte” Hospital, University of Insubria, 21100 Varese, VA, Italy
| | - Tommaso Bernardini
- Department of Obstetrics and Gynecology, Policlinico Hospital, 35031 Abano Terme, PD, Italy; (M.S.); (B.A.V.); (T.B.); (N.F.)
| | - Nicola Fattizzi
- Department of Obstetrics and Gynecology, Policlinico Hospital, 35031 Abano Terme, PD, Italy; (M.S.); (B.A.V.); (T.B.); (N.F.)
| | - Manuela Neri
- Obstetrics and Gynecology, University of Cagliari, 09124 Cagliari, CA, Italy; (M.N.); (S.G.)
- Department of Obstetrics and Gynecology, Azienda Ospedaliero Universitaria, Policlinico Universitario Duilio Casula, 09045 Monserrato, CA, Italy
| | - Stefano Guerriero
- Obstetrics and Gynecology, University of Cagliari, 09124 Cagliari, CA, Italy; (M.N.); (S.G.)
- Department of Obstetrics and Gynecology, Azienda Ospedaliero Universitaria, Policlinico Universitario Duilio Casula, 09045 Monserrato, CA, Italy
| |
Collapse
|
41
|
A rare case of ovarian adenomyoma mimicking primary invasive ovarian cancer with a contralateral serous borderline ovarian tumor: A case report and review of the literature. Heliyon 2020; 6:e04406. [PMID: 32743088 PMCID: PMC7385463 DOI: 10.1016/j.heliyon.2020.e04406] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2020] [Revised: 06/20/2020] [Accepted: 07/03/2020] [Indexed: 01/23/2023] Open
Abstract
Extrauterine adenomyoma is a rare type of benign tumor, characterized by nodular aggregate of smooth muscle, endometrial glands and endometrial stroma, arising outside the uterus. In this study we describe a case of primary ovarian adenomyoma associated with endometriotic cysts with contralateral serous borderline tumor in a 40-year-old woman and we highlight how preoperative exams could lead to the suspicious of invasive cancer. We provide a review of the literature, analyzing all cases of extrauterine adenomyoma published so far, classifying them on the basis of pathogenetic theories proposed, localization of the lesion, imaging modalities and treatment adopted.
Collapse
|
42
|
Bielen D, Tomassetti C, Van Schoubroeck D, Vanbeckevoort D, De Wever L, Van den Bosch T, D'Hooghe T, Bourne T, D'Hoore A, Wolthuis A, Van Cleynenbreughel B, Meuleman C, Timmerman D. IDEAL study: magnetic resonance imaging for suspected deep endometriosis assessment prior to laparoscopy is as reliable as radiological imaging as a complement to transvaginal ultrasonography. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2020; 56:255-266. [PMID: 31503381 DOI: 10.1002/uog.21868] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Revised: 07/18/2019] [Accepted: 08/27/2019] [Indexed: 06/10/2023]
Abstract
OBJECTIVE To compare the value of using one-stop magnetic resonance imaging (MRI) vs standard radiological imaging as a supplement to transvaginal ultrasonography (TVS) for the preoperative assessment of patients with endometriosis referred for surgery in a tertiary care academic center. METHODS This prospective observational study compared the diagnostic value of the standard preoperative imaging practice of our center, which involves expert TVS complemented by intravenous urography (IVU) for the evaluation of the ureters and double-contrast barium enema (DCBE) for the evaluation of the rectum, sigmoid and cecum, with that of expert TVS complemented by a 'one-stop' MRI examination evaluating the upper abdomen, pelvis, kidneys and ureters as well as rectum and sigmoid on the same day, for the preoperative triaging of 74 women with clinically suspected deep endometriosis. The findings at laparoscopy were considered the reference standard. Patients were stratified according to their need for monodisciplinary surgical approach, carried out by gynecologists only, or multidisciplinary surgical approach, involving abdominal surgeons and/or urologists, based on the extent to which endometriosis affected the reproductive organs, bowel, ureters, bladder or other abdominal organs. RESULTS Our standard preoperative imaging approach and the combined findings of TVS and MRI had similar diagnostic performance, resulting in correct stratification for a monodisciplinary or a multidisciplinary surgical approach of 67/74 (90.5%) patients. However, there were differences between the estimation of the severity of disease by DCBE and MRI. The severity of rectal involvement was underestimated in 2.7% of the patients by both TVS and DCBE, whereas it was overestimated in 6.8% of the patients by TVS and/or DCBE. CONCLUSIONS Complementary to expert TVS, 'one-stop' MRI can predict intraoperative findings equally well as standard radiological imaging (IVU and DCBE) in patients referred for endometriosis surgery in a tertiary care academic center. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- D Bielen
- Department of Radiology, KU Leuven University Hospitals, Leuven, Belgium
- Department of Imaging and Pathology, KU Leuven University Hospitals, Leuven, Belgium
| | - C Tomassetti
- Leuven University Fertility Center, KU Leuven University Hospitals, Leuven, Belgium
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
- Department of Development and Regeneration, KU Leuven University Hospitals, Leuven, Belgium
| | - D Van Schoubroeck
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
| | - D Vanbeckevoort
- Department of Radiology, KU Leuven University Hospitals, Leuven, Belgium
| | - L De Wever
- Department of Radiology, KU Leuven University Hospitals, Leuven, Belgium
| | - T Van den Bosch
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
| | - T D'Hooghe
- Leuven University Fertility Center, KU Leuven University Hospitals, Leuven, Belgium
- Global Medical Affairs Fertility, Merck Healthcare KGaA, Darmstadt, Germany
| | - T Bourne
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
- Department of Gynecology and Obstetrics, Imperial College Healthcare NHS Trust, London, UK
| | - A D'Hoore
- Department of Abdominal Surgery, KU Leuven University Hospitals, Leuven, Belgium
- Department of Oncology, KU Leuven University Hospitals, Leuven, Belgium
| | - A Wolthuis
- Department of Abdominal Surgery, KU Leuven University Hospitals, Leuven, Belgium
- Department of Oncology, KU Leuven University Hospitals, Leuven, Belgium
| | | | - C Meuleman
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
- Department of Development and Regeneration, KU Leuven University Hospitals, Leuven, Belgium
- Leuven University Endometriosis Center, KU Leuven University Hospitals, Leuven, Belgium
| | - D Timmerman
- Department of Obstetrics and Gynecology, KU Leuven University Hospitals, Leuven, Belgium
- Department of Development and Regeneration, KU Leuven University Hospitals, Leuven, Belgium
| |
Collapse
|
43
|
Virgilio BA, Pontrelli G, Fattizzi N, Sacchi D, Basile F, Noventa M, Scioscia M. Endometrioid borderline ovarian tumor arising from endometriotic cyst: short-term change of sonographic appearance. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2020; 55:692-694. [PMID: 31568603 DOI: 10.1002/uog.21875] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/01/2019] [Revised: 09/08/2019] [Accepted: 09/09/2019] [Indexed: 06/10/2023]
Affiliation(s)
- B A Virgilio
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| | - G Pontrelli
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| | - N Fattizzi
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| | - D Sacchi
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy
| | - F Basile
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| | - M Noventa
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| | - M Scioscia
- Department of Obstetrics and Gynecology, Policlinico Abano Terme, Abano Terme, Padua, Italy
| |
Collapse
|
44
|
Bean E, Chaggar P, Thanatsis N, Dooley W, Bottomley C, Jurkovic D. Intra- and interobserver reproducibility of pelvic ultrasound for the detection and measurement of endometriotic lesions. Hum Reprod Open 2020; 2020:hoaa001. [PMID: 32161818 PMCID: PMC7060019 DOI: 10.1093/hropen/hoaa001] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 12/16/2019] [Indexed: 01/04/2023] Open
Abstract
STUDY QUESTION What is the interobserver and intraobserver reproducibility of pelvic ultrasound for the detection of endometriotic lesions? SUMMARY ANSWER Pelvic ultrasound is highly reproducible for the detection of pelvic endometriotic lesions. WHAT IS KNOWN ALREADY Transvaginal ultrasound (TVS) has been widely adopted as the first-line assessment for the diagnosis and assessment of pelvic endometriosis. Severity of endometriosis as assessed by ultrasound has been shown to have good concordance with laparoscopy (kappa 0.79). The reproducibility of TVS for assessment of ovarian mobility and pouch of Douglas obliteration using the 'sliding sign' has already been described in the literature. However, there is no available data in the literature to demonstrate the intraobserver repeatability of measurements for endometriotic cysts and nodules. STUDY DESIGN SIZE DURATION This was a prospective observational cross-sectional study conducted over a period of 12 months. We included 50 consecutive women who were all examined by two operators (A and B) during their clinic attendance. PARTICIPANTS/MATERIALS SETTING METHODS The study was carried out in a specialist endometriosis centre. We included all consecutive women who had ultrasound scans performed independently by two experienced operators during the same visit to the clinic. The outcomes of interest were the inter- and intraobserver reproducibility for the detection of endometriotic lesions. We also assessed repeatability of the measurements of lesion size. MAIN RESULTS AND THE ROLE OF CHANCE There was a good level of agreement between operator A and operator B in detecting the presence of pelvic endometriotic lesions (k = 0.72). There was a very good level of agreement between operators in identifying endometriotic cysts (k = 0.88) and a good level of agreement in identifying endometriotic nodules (k = 0.61). The inter- and intraobserver repeatability of measuring endometriotic cysts was excellent (intra-class correlation (ICC) ≥ 0.98). There was good interobserver measurement repeatability for bowel nodules (ICC 0.88), but the results for nodules in the posterior compartment were poor (ICC 0.41). The intraobserver repeatability for nodule size measurements was good for both operators (ICC ≥0.86). LIMITATIONS REASONS FOR CAUTION Within this cohort, there was insufficient data to perform a separate analysis for nodule size in the anterior compartment. All examinations were performed within a specialised unit with a high prevalence of deep endometriosis. Our findings may not apply to operators without intensive ultrasound training in the diagnosis of pelvic endometriosis. WIDER IMPLICATIONS OF THE FINDINGS These findings are important because ultrasound has been widely accepted as the first-line investigation for the diagnosis of pelvic endometriosis, which often determines the need for future investigations and treatment. The detection and measurement of bowel nodules is essential for anticipation of surgical risk and planning surgical excision. STUDY FUNDING/COMPETING INTERESTS The authors have no conflict of interest. No funding was obtained for this work.
Collapse
Affiliation(s)
- E Bean
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, Lower Ground Floor, 235 Euston Road, London NW1 2BU, UK
| | - P Chaggar
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, Lower Ground Floor, 235 Euston Road, London NW1 2BU, UK
| | - N Thanatsis
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, Lower Ground Floor, 235 Euston Road, London NW1 2BU, UK
| | - W Dooley
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, Lower Ground Floor, 235 Euston Road, London NW1 2BU, UK
| | | | - D Jurkovic
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, Lower Ground Floor, 235 Euston Road, London NW1 2BU, UK
| |
Collapse
|
45
|
Bean E, Cutner A, Saridogan E, Wong M, Naftalin J, Jurkovic D. Hemoperitoneum as a precursor of deep pelvic endometriosis: prospective cohort study. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2019; 54:389-394. [PMID: 30677178 DOI: 10.1002/uog.20222] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Revised: 01/10/2019] [Accepted: 01/15/2019] [Indexed: 06/09/2023]
Abstract
OBJECTIVE To determine whether significant hemoperitoneum could be a precursor of deep pelvic endometriosis in non-pregnant premenopausal women presenting with severe acute lower abdominal pain. METHODS This was a prospective observational cohort study carried out at a dedicated gynecological diagnostic unit over a period of 18 months. We included consecutive non-pregnant, premenopausal women who attended with severe acute lower abdominal pain and underwent a pelvic ultrasound examination. Women were triaged for surgical or conservative management depending on the cause of pain and severity of their symptoms. Those who were selected for conservative management were invited for follow-up ultrasound scans. The main outcome measure was evidence of newly developed deep endometriosis at follow-up examination. RESULTS Of 118 non-pregnant women who attended our unit with severe acute lower abdominal pain, 20 underwent emergency surgery and 17 had a history of endometriosis, or evidence of endometriosis on the initial scan, and were excluded from the study. Therefore, conservative management was employed in 81 women, eight of whom had evidence of significant hemoperitoneum at presentation. A total of 35 women attended for all follow-up ultrasound scans. At the completion of follow-up, four of six (67% (95% CI, 22-96%)) women who presented initially with significant intra-abdominal bleeding had developed new evidence of deep endometriosis, compared with one of 29 (3% (95% CI, 0-18%)) of those without hemoperitoneum (relative risk, 19.3 (95% CI, 3-144); P < 0.001). CONCLUSION In some women, the presence of significant hemoperitoneum that is managed conservatively precedes the development of deep endometriosis. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- E Bean
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - A Cutner
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - E Saridogan
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - M Wong
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - J Naftalin
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| | - D Jurkovic
- Gynaecology Diagnostic and Outpatient Treatment Unit, Elizabeth Garrett Anderson Wing, University College London Hospital, London, UK
| |
Collapse
|
46
|
Scala C, Leone Roberti Maggiore U, Barra F, Tantari M, Ferrero S. Impact of Endometriomas and Deep Infiltrating Endometriosis on Pregnancy Outcomes and on First and Second Trimester Markers of Impaired Placentation. ACTA ACUST UNITED AC 2019; 55:medicina55090550. [PMID: 31480321 PMCID: PMC6780829 DOI: 10.3390/medicina55090550] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Revised: 08/10/2019] [Accepted: 08/26/2019] [Indexed: 02/07/2023]
Abstract
Background and objective: Previous studies did not draw a definitive conclusion about the influence of the role of deep endometriosis (DE) and ovarian endometrioma (OE) as risk factor for developing adverse perinatal outcomes in patients affected by endometriosis. This study aimed to investigate if adverse fetal and maternal outcomes, and in particular the incidence of small for gestational age (SGA) infants, are different in pregnant women with OE versus pregnant women with DE without OE. Material and methods: This study was based on a retrospective analysis of a database collected prospectively. The population included in the study was divided into three groups: patients with OE, patients with DE without concomitant OE, and patients without endometriosis (controls). The controls were matched on the basis of age and parity. Demographic data at baseline and pregnancy outcomes were recorded. Results: There was no statistically significant difference in first trimester levels of PAPP-A, first and mid-pregnancy trimester mean Uterine Artery Doppler pulsatile index, estimated fetal weight centile, and SGA fetuses' prevalence for patients with OE, and those with DE without OE in comparison to health women; moreover, there was no statistically significant difference with regard to SGA birth prevalence, prevalence of preeclampsia, and five-minute Apgar score between these three groups. Conclusions: The specific presence of OE or DE in pregnant women does not seem to be associated with an increased risk of delivering an SGA infant. These data seem to suggest that patients with endometriosis should be treated in pregnancy as the general population, thus not needing a closer monitoring.
Collapse
Affiliation(s)
- Carolina Scala
- Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, 16126 Genoa, Italy
| | - Umberto Leone Roberti Maggiore
- Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, 16126 Genoa, Italy
| | - Fabio Barra
- Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, 16126 Genoa, Italy
| | - Matteo Tantari
- Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, 16126 Genoa, Italy
| | - Simone Ferrero
- Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy.
- Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, 16126 Genoa, Italy.
- Piazza della Vittoria 14 S.r.l., 16121 Genova, Italy.
| |
Collapse
|
47
|
Hidari T, Hirata T, Arakawa T, Koga K, Neriishi K, Fukuda S, Nakazawa A, Nagashima N, Ma S, Sun H, Takamura M, Harada M, Hirota Y, Wada-Hiraike O, Fujii T, Osuga Y. Contralateral ovarian endometrioma recurrence after unilateral salpingo-oophorectomy. BMC WOMENS HEALTH 2019; 19:59. [PMID: 31046768 PMCID: PMC6498560 DOI: 10.1186/s12905-019-0760-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/01/2019] [Accepted: 04/22/2019] [Indexed: 11/17/2022]
Abstract
Background The recurrence rate after unilateral salpingo-oophorectomy (USO) for unilateral endometrioma has not been reported. We evaluated the rate of and risk factors for endometrioma recurrence after USO. Methods In this retrospective observational study, we enrolled 110 women (age, 35–45 years) who underwent laparoscopic USO (n = 50) or cystectomy (n = 60) for unilateral ovarian endometrioma from January 2010 through December 2012. We compared patients’ characteristics between patients who underwent USO and those who underwent cystectomy. We also compared patients with and without an endometrioma recurrence after USO using univariate and multivariate stepwise logistic regression models to identify recurrence risk factors. Endometrioma recurrence was defined as an ovarian cyst (> 2 cm) with features typical of an endometrioma identified by postoperative transvaginal sonography. Results Endometrioma recurred in 8 (16%) patients after USO (mean follow-up, 46.0 ± 12.9 months [range, 15–73]). The post-USO cumulative recurrence rates at 12, 24, 36, and 60 months were 8.0, 10.2, 12.7, and 24.7%, respectively (Kaplan-Meier analysis). In logistic regression analysis, a contralateral side adhesion score ≥ 4 was an independent risk factor for endometrioma recurrence after USO (odds ratio, 19.48, 95% confidence interval, 1.59–237.72). The post-USO cumulative recurrence rates at 12, 24, 36, and 57 months were 19.5, 24.1, 31.0, and 54.0%, respectively, in cases with contralateral side adhesion scores ≥4, and 0.0, 0.0, 0.0, and 5.9%, respectively, in cases with scores < 4 (log-rank test, P = 0.0023). Conclusions To our knowledge, this is the first report on the recurrence rate and risk factors associated with recurrence after USO. Endometrioma recurrence rates were 24.7% during the first 5 years after USO. The post-USO recurrence rate increased significantly in cases with contralateral side adhesions. Our findings could improve the planning of USO and patient selection for postoperative hormonal therapy.
Collapse
Affiliation(s)
- Tokie Hidari
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Tetsuya Hirata
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
| | - Tomoko Arakawa
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Kaori Koga
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Kazuaki Neriishi
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Shinya Fukuda
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Akari Nakazawa
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Natsuki Nagashima
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Suke Ma
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Hui Sun
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Masashi Takamura
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Miyuki Harada
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Yasushi Hirota
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Osamu Wada-Hiraike
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Tomoyuki Fujii
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| | - Yutaka Osuga
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan
| |
Collapse
|
48
|
Moro F, Pasciuto T, Djokovic D, Di Legge A, Granato V, Moruzzi MC, Mancari R, Zannoni GF, Fischerova D, Franchi D, Scambia G, Testa AC. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. ULTRASOUND IN OBSTETRICS & GYNECOLOGY : THE OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIETY OF ULTRASOUND IN OBSTETRICS AND GYNECOLOGY 2019; 53:116-123. [PMID: 29978587 DOI: 10.1002/uog.19174] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2018] [Revised: 06/21/2018] [Accepted: 07/01/2018] [Indexed: 06/08/2023]
Abstract
OBJECTIVES To investigate ultrasound features and the best cut-off value of the cancer antigen 125/carcinoembryonic antigen (CA125/CEA) ratio to discriminate ovarian metastases from benign and primary malignant ovarian neoplasms in two selected groups of morphological ovarian masses, namely multilocular masses with five or more locules and multilocular-solid masses. METHODS Patients with multilocular (five or more locules) or multilocular-solid ovarian masses, operated on within 3 months of ultrasound examination, and with tumor markers (CEA and CA125) available at diagnosis, were identified retrospectively from three ultrasound centers. The masses were described using the International Ovarian Tumor Analysis (IOTA) terminology. Ultrasound and clinical characteristics were compared between those with an ovarian neoplasm (including benign and primary malignant neoplasms) and those with an ovarian metastasis. Receiver-operating characteristics curve (ROC) analysis was used to evaluate the ability of CA125, CEA and CA125/CEA to differentiate between ovarian neoplasms and ovarian metastases, and their predictive performance was assessed. RESULTS In total, 350 (88.4%) patients with an ovarian neoplasm (including 99 benign, 43 borderline and 197 primary epithelial ovarian carcinomas, seven malignant rare tumors and four other types of invasive ovarian tumor) and 46 (11.6%) patients with an ovarian metastasis were analyzed. On ultrasound examination, ovarian neoplasms were smaller than ovarian metastases (median largest diameter, 97 (range, 20-387) mm vs 146 (range, 43-259) mm, respectively; P < 0.0001) and presented with a lower number of cysts with > 10 locules (18.9% vs 54.3%; P < 0.0001). ROC curve analysis showed that the best cut-off value of CEA for distinguishing between ovarian neoplasms and ovarian metastases was 2.33 ng/mL. The predictive performance of this CEA cut-off value was: area under the curve (AUC), 0.791 (95% CI, 0.711-0.870); accuracy, 73.7%; sensitivity, 73.1%; specificity, 78.3%; positive predictive value (PPV), 96.2%; and negative predictive value (NPV), 27.7%. The best cut-off value of CA125/CEA for distinguishing between ovarian neoplasms and ovarian metastases was 11.92. The predictive performance of this CA125/CEA cut-off value was: AUC, 0.758 (95% CI, 0.683-0.833); accuracy, 79.8%; sensitivity, 82.3%; specificity, 60.9%; PPV, 94.1%; and NPV, 31.1%. CONCLUSIONS CA125/CEA ratio and CEA alone did not show any significant difference in their ability to distinguish between ovarian neoplasms (including benign and malignant) and ovarian metastases in masses with multilocular and those with multilocular-solid morphology. Therefore, in this morphological subgroup of ovarian masses, CEA alone is sufficient to differentiate between ovarian neoplasms and ovarian metastases. Copyright © 2018 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- F Moro
- Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - T Pasciuto
- Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - D Djokovic
- Istituto di Ginecologia e Ostericia Università Cattolica del Sacro Cuore, Rome, Italy
| | - A Di Legge
- Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - V Granato
- Istituto di Ginecologia e Ostericia Università Cattolica del Sacro Cuore, Rome, Italy
| | - M C Moruzzi
- Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
- Gynecological Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - R Mancari
- Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology, Milan, Italy
| | - G F Zannoni
- Institute of Histopathology, Università Cattolica del Sacro Cuore, Rome, Italy
| | - D Fischerova
- Gynecological Oncology Center, Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University, Prague, Czech Republic
| | - D Franchi
- Preventive Gynecology Unit, Division of Gynecology, European Institute of Oncology, Milan, Italy
| | - G Scambia
- Dipartimento Scienze della Salute della Donna e del Bambino, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy
| | - A C Testa
- Istituto di Ginecologia e Ostericia Università Cattolica del Sacro Cuore, Rome, Italy
| |
Collapse
|
49
|
Clinical evaluation and management of endometriosis: guideline for Korean patients from Korean Society of Endometriosis. Obstet Gynecol Sci 2018; 61:553-564. [PMID: 30254991 PMCID: PMC6137012 DOI: 10.5468/ogs.2018.61.5.553] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2017] [Revised: 03/30/2018] [Accepted: 04/24/2018] [Indexed: 12/04/2022] Open
Abstract
Endometriosis is one of the most common diseases in reproductive ages, and it affects patients' quality of life and fertility. However, few Korean guidelines are available for the evaluation and management of endometriosis. Korean Society of Endometriosis reviewed various literatures and trials, and to provide seventy-one evidence-based recommendations. This review presents guidelines for the diagnosis and management of endometriosis with emphasis on: it's role in infertility, treatment of recurrence, asymptomatic women, endometriosis in adolescents and menopausal women, and possible association of endometriosis with cancer.
Collapse
|
50
|
Eisenberg VH, Alcazar JL, Arbib N, Schiff E, Achiron R, Goldenberg M, Soriano D. Applying a statistical method in transvaginal ultrasound training: lessons from the learning curve cumulative summation test (LC-CUSUM) for endometriosis mapping. ACTA ACUST UNITED AC 2017; 14:19. [PMID: 29046621 PMCID: PMC5626798 DOI: 10.1186/s10397-017-1022-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2017] [Accepted: 09/08/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND Methods available for assessing the learning curve, such as a predefined number of procedures or direct mentoring are lacking. Our aim was to describe the use of a statistical method to identify the minimal training length of an experienced sonographer, newly trained in deep infiltrating endometriosis (DIE) mapping by evaluating the learning curve of transvaginal ultrasound (TVUS) in the preoperative assessment of endometriosis. METHODS A retrospective study in a tertiary referral center for endometriosis. Reports and stored data from TVUS scans performed by one operator with training in general gynecological ultrasound, but not in endometriosis mapping, were analyzed retrospectively for patients who subsequently underwent laparoscopy, which served as a reference standard. The performance of TVUS was assessed for the following sites: endometriomas, bladder, vagina, pouch of Douglas, bowel and uterosacral ligaments, and correlated with laparoscopic findings. Sensitivity, specificity, PPV, NPV, and accuracy were calculated, and the operator's diagnostic performance was assessed using the learning curve cumulative summation test (LC-CUSUM). RESULTS Data from 94 women were available for analysis. The learning curve using the LC-CUSUM graph showed that the sonographer reached the predefined level of proficiency in detecting endometriosis lesions after 20, 26, 32, 31, 38, and 44 examinations for endometriomas, bladder nodules, vaginal nodules, pouch of Douglas obliteration, bowel nodules, and uterosacral ligament nodules, respectively. CONCLUSIONS LC-CUSUM allows monitoring of individual performance during the learning process of new methodologies. This study shows that a sonographer trained in general gynecologic ultrasonography, who devotes time to learn TVUS for DIE mapping, can achieve proficiency for diagnosing the major types of endometriotic lesions after examining less than 50 patients who subsequently undergo surgery in a training setting.
Collapse
Affiliation(s)
- Vered H Eisenberg
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| | - Juan L Alcazar
- Department of Obstetrics and Gynecology, Clinica Universidad de Navarra, University of Navarra, Pamplona, Spain
| | - Nissim Arbib
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| | - Eyal Schiff
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| | - Reuven Achiron
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| | - Motti Goldenberg
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| | - David Soriano
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Tel-Aviv University, 52621 Ramat Gan, Israel
| |
Collapse
|